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2 Summary  
 
Hedgehog signaling (Hh) plays a crucial role in vital processes such as embryonic 
development or cell homeostasis. Aberrant Hh signaling is linked to formation, progression 
and growth of tumors.  
 
The canonical Hh signaling cascade is initiated by binding of the Hh ligand to its receptor 
Patched1 (PTCH1) (Hooper and Scott 1989; Nakano et al. 1989), a transmembrane protein 
located in the ciliary membrane which relieves the repression of the membrane-bound G 
protein-coupled receptor (GPCR) Smoothened (SMO) which activates the Hh 
transcriptional factors, zinc finger proteins of the GLI (Cubitus interruptus (Ci) in Drosophila 
melanogaster) family (Hui and Angers 2011). The Hh signaling pathway is reported to 
activate downstream kinases which in turn lead to various cellular processes such as 
differentiation, polarity and proliferation. 
 
The so-called dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) are 
induced by Hh activation and a slight change in their amount could lead to large and 
significant effects on various cellular processes. DYRK1A as a candidate gene is 
responsible for the altered neuronal development and brain abnormalities in Down 
syndrome (DS, OMIM #190685). DYRK1B is known to be associated with the metabolic 
syndrome and, is commonly amplified in ovarian and pancreatic cancer (Friedman 2010a; 
Keramati et al. 2014b).  
 
The results of the present work have shown, that Hh signaling induces DYRK1B and this 
kinase has been shown to have a regulatory kinetic effect on Hh signaling pathway, as 
short-term inhibition of DYRK1B kinase leads to increase in GLI protein levels and long-
term inhibition has shown to deplete the protein levels of GLI. This strong fluctuation in the 
kinase could be detrimental in a therapeutical context, as DYRK1B has been shown to 
regulate PI3K/mTOR/AKT signaling pathway which is subject to strong feedback regulation 
and can induce oncogenic Hh signaling. Combination therapy which targets DYRK1B and 
other signaling pathway components such as mTOR, AKT, S6K were used to deplete 
growth of pancreatic and ovarian cancer cells.  
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Hh signaling exerts myriad functions and one of the functions is to induce acetylation of 
microtubules and of Acetylated Tubulin (AcTub)-dependent processes such as cell 
polarization or organelle transport. With my results, I find that Hh signaling increases 
DYRK1B levels, which inactivates Glycogen synthase kinase 3β (GSK3β) through Serine 9 
(Ser9) phosphorylation, resulting in Histone Deacetylase 6 (HDAC6) inhibition and 
increased tubulin acetylation. In summary, I have described a mechanistic framework of 
how intercellular communication can impinge on cytoskeletal regulation and cell function 
via Hh signal transduction.  
 
Considering these effects, I have shown that DYRK1B is one of the very crucial kinases 
mediating multiple signaling pathways and; thereby, it’s extremely important to elucidate 
the mechanistic framework of its action.
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3 Zusammenfassung 
 
Der Hedgehog-Signalweg (Hh) spielt eine entscheidende Rolle bei lebenswichtigen 
Prozessen wie der Embryonalentwicklung oder der Zellhomöostase. Eine abweichende 
Signalweiterleitung ist mit der Bildung und Progression/Wachstum von Tumoren 
verbunden.  
 
Die kanonische Hh - Signalkaskade wird initiiert durch Bindung des Hh- Liganden an seinen 
Rezeptor Patched1 (PTCH1) (Hooper and Scott 1989; Nakano et al. 1989), ein in der 
Ciliarmembran lokalisiertes Transmembranprotein, welches im ungebundenen Zustand die 
Aktivität des membrangebundenen G-Protein-gekoppelten Rezeptors (GPCR) 
Smoothened (SMO) reprimiert. Die Bindung aktiviert Hh-Transkriptionseffektoren, die 
Zinkfingerproteine der GLI Familie (Cubitus interruptus (Ci) in Drosophila melanogaster) 
(Hui and Angers 2011). Es wurde gezeigt, dass der Hh-Signalweg nachgeschaltete Kinasen 
aktiviert, die wiederum zu verschiedenen zellulären Prozessen führen. So wird 
beispielsweise die Expression der DYRK-Kinasen (dual-specificity tyrosine 
phosphorylation-regulated kinases) durch Hh-Aktivierung induziert. Bereits geringfügige 
Veränderungen ihrer Expression können zu großen und signifikanten Effekten auf 
verschiedene zelluläre Prozesse führen.  
 
DYRK1A ist ein Kandidaten, das für veränderte neuronale Entwicklung und Hirnanomalien 
beim Down-Syndrom verantwortlich ist (DS, OMIM # 190685). Weiterhin ist bekannt, dass 
DYRK1B mit dem metabolischen Syndrom assoziiert ist und bei Ovarial- und 
Pankreaskrebs häufig verstärkt exprimiert wird (Friedman 2010a; Keramati et al. 2014b).  
 
Die Ergebnisse der vorliegenden Arbeit konnten zeigen, dass der Hh-Signalweg die 
Expression von DYRK1B induziert, was wiederum einen regulatorischen kinetischen Effekt 
auf den Hh-Signalweg hat, da die Kurzzeit-Hemmung der DYRK1B-Kinase zu Erhöhung 
des GLI-Proteinlevels führt, wohingegen eine Langzeit-Hemmung den GLI-Proteinlevel 
verringert. Diese starken Schwankungen der Kinase könnten therapeutisch schädlich sein, 
da gezeigt wurde, dass DYRK1B den PI3K / mTOR / AKT-Signalweg reguliert, der einer 
starken Rückkopplungsregulation unterliegt und onkogene Hh-Signale induzieren kann. 
Eine Kombinationstherapie, die auf DYRK1B und andere Signalwegkomponenten wie 
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mTOR, AKT, S6K wirkt, wurde verwendet, um das Wachstum von Pankreas- und 
Ovarialkrebszellen zu verringern. 
 
Der Hh-Signalweg steuert unzählige Funktionen. Eine dieser Funktionen ist die 
Acetylierung von Mikrotubuli und von AcTub-abhängigen Prozessen wie Zellpolarisation 
oder Organellentransport. Im Zuge dieser Arbeit konnte gezeigt werden, dass der Hh-
Signalweg DYRK1B-Level erhöht, wodurch Glycogen-Synthase-Kinase 3β (GSK3β) durch 
Ser9-Phosphorylierung inaktiviert wird, was zu einer HDAC6-Inhibierung führt und die 
Tubulin-Acetylierung erhöht. In dieser Arbeit wird ein mechanistisches Zusammenspiel 
beschrieben, wie interzelluläre Kommunikation über die Hh Signaltransduktion auf die 
Zytoskelett-Regulation und Zellfunktionen einwirken kann.  
 
In Hinblick auf die vielfältigen Die Auswirkungen von DYRK1B auf verschiedene wichtige 
Signalwege von Krebs und Entwicklung, die weitere Erforschung seiner Bedeutung ist von 
höchstem Interesse. 
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4 Introduction 
 
Intercellular signaling and signal transduction underlie several aspects of development and 
behavior. Core intercellular signaling pathways found in animal cells include Notch, Wnt, 
BMP/TGFβ, Hedgehog, growth factor signaling and others (Housden and Perrimon 2014). 
These pathways provide a central means of communication between cells. This intercellular 
communication controls almost every aspect of cellular functions such as cell proliferation, 
migration, recognition, and differentiation (Uriu et al. 2014). Various modulators of the 
signaling pathways such as, the ligands, receptors, transducers, and regulators are known 
which provide a better understanding of the multifunctional cellular system and also serve 
as drug targets. 
 
Cell-cell communication is often mediated by protein molecules within a cell that is 
recognized by specific receptors presenting on neighboring cells. These intracellular 
signaling events can occur among distinct cell types (paracrine signaling) and within the 
same cell type (autocrine signaling). Intracellular communication can occur  via indirect 
interactions (autocrine, paracrine) where, the secreted ligands, such as growth factors, 
cytokines, and chemokines, bind to specific receptors expressed on neighboring cells and 
direct interactions (juxtacrine communication) where a cell-cell contact is required for 
triggering the signaling as ligands are expressed on the plasma membrane of neighboring 
cells. Various downstream signaling pathways are activated through dynamic post-
translational modifications and protein-protein interactions upon activation of membrane 
receptors, which in turn lead to the modulation of several cellular functions (Scott and 
Pawson 2009).  
 
Intercellular signal transduction also plays an important role in embryonic development by 
significantly affecting cell growth, differentiation, and morphogenesis. Several reports have 
shown that early embryogenesis and tumorigenesis share several similarities, in terms of 
cell invasive behavior, epigenetic regulation, protein profiling and other biological behaviors 
(Ma et al. 2010). The hallmark of embryonic development is ‘regulation’, the trend that cells 
follow to arrange themselves into organized structures whereas cancer is characterized by 
‘dysregulation’ and ‘disorder’. The process of embryogenesis involves spatial and temporal 
activation of developmental signaling pathways (Dominic Poccia 2006). Re-activation of 
these embryonic signals in adult cells- due to mutations and epigenetic remodeling is one 
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of the major causes of cancer. Several important developmental pathways which include 
Wnt, Hedgehog, and Notch pathways, are mostly, dysregulated in tumor progression, 
initiation, and maintenance of metastatic spread and growth.  
 
4.1 Hedgehog Signaling Pathway 
 
The Hedgehog (Hh) Signaling pathway plays a significant role in tissue homeostasis, 
metabolism control, embryogenesis, and various other developmental processes. It 
regulates the differentiation and proliferation of cells, body patterning, stem cell 
maintenance, survival, and affects the oncogenic transformation and the development of 
tumors (Varjosalo and Taipale 2008; Gupta et al. 2010a; Briscoe and Therond 2013; 
Teperino et al. 2014; D’Amico et al. 2015; Lee et al. 2016b). 
 
In 1980 Eric F. Wieschaus and Nusslein-Volhard  discovered the Hedgehog (HH) gene 
during their genetic screens for mutations that disrupt the larval body plan in Drosophila 
melanogaster (Nusslein-Volhard and Wieschaus 1980). The Drosophila larva is segmented, 
with a smooth posterior end and a bristle coated anterior end, known as denticles. This 
segmental patterning was shown to be affected by polarity mutants in their mutational 
screen. Polarity mutants led to the failed development of the posterior part, which in turn 
resulted in a short and spiky phenotype, resembling a Hedgehog and hence the name 
(Nusslein-Volhard and Wieschaus 1980; Ingham and McMahon 2001; van den Brink 2007; 
Varjosalo and Taipale 2008).  
 
Three Hedgehog homologs are known to be present in vertebrates, namely: Desert (DHH), 
Indian (IHH), and Sonic (SHH). In mouse and humans, the three hedgehog genes are highly 
conserved (Marigo et al. 1995). Specific roles for all the three genes have been found 
(Echelard et al. 1993; Riddle et al. 1993; Roelink et al. 1994; Ingham and McMahon 2001) 
such as: SHH regulates the polarizing activity of the organizing centers located in the limb 
bud, the notochord, or the floor plate of the neural tube (Cohn and Tickle 1996; Jessell 
2000; Singh and Lauth 2017), endochondral bone development, osteoblast differentiation 
and various other cellular events are regulated by IHH (St-Jacques et al. 1999; McMahon 
et al. 2003; Singh and Lauth 2017). Amongst the three, the least studied homolog is DHH. 
Several reports suggest it regulates the development of germ cells in testes and peripheral 
nerve sheath formation (Park et al. 2007; Singh and Lauth 2017).  
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The hedgehog proteins go through comprehensive and specific post-translational 
modifications and cleavage events producing ~45 kDa precursor protein. This precursor 
protein is autocatalytically cleaved and giving rise to a cholesterol modified 19 kDa NH2-
terminal fragment (HhNp), which undergoes dual lipid modification and an unmodified 26 
kDa COOH terminal fragment (HhC,(lacking the palmitate modification)) (Porter et al. 1996), 
which acts as a cholesterol transferase and also catalyzes the cleavage (Lee et al. 1994; 
Marti et al. 1995). The most striking feature of hedgehog proteins is the dual lipid 
modification of the 19 kDa NH2 terminal fragment. The modified signaling protein is 
covalently linked to cholesterol and palmitate groups and is poorly soluble. Palmitoylation 
is critical for effective long and short-range signaling. Attachment of palmitate to Hh proteins 
is independent of cholesterol modification and autoprocessing and is catalyzed by HHAT 
(Hedgehog acyltransferase). HHAT is the member of membrane-bound O-acyltransferase 
(MBOAT) family, a subgroup of multipass membrane proteins that catalyze transfer of fatty 
acyl groups to lipids and proteins. Mutations in HHAT produce a phenotype that is similar 
to loss of Hh function (Lee et al. 1994; Marti et al. 1995; Porter et al. 1996; Chamoun et al. 
2001; van den Brink 2007; Buglino and Resh 2012). It was also recently shown that 
palmitoylation promotes cleavage of N-terminal amino acids by a disintegrin and 
metalloproteases (ADAM) family of proteases (Ohlig et al. 2011; Koleva et al. 2015). This 
kind of cleavage leads to the formation of active Shh multimers. The amino acid residues, 
if not cleaved can affect SHH, as they are shown to interact with the Zn2+ coordination sites 
on adjacent molecules and this region has been shown to interact with Patched and is 
known to modulate SHH activity and stability (Day et al. 1999; Fuse et al. 1999; Bosanac et 
al. 2009a).  
 
Hh proteins undergo cholesterylation, a post-translational modification (Ciepla et al. 2015) 
at their C-termini (Porter et al. 1996) which increases their membrane affinity and restricts 
their dispersal (Gallet 2011). Mutant Hh proteins lacking the cholesterol modification have 
a longer range of distribution and signaling, which can lead to patterning defects (Li et al. 
2006; Huang et al. 2007). Dispatched (Disp), a 12- pass transmembrane protein related to 
the bacterial RND (Resistance nodulation-cell division) family of transporters is essential for 
the release of Hh from cell surfaces and its long-range signaling activities. Mutants from 
dispatched retain cholesterol-modified Hh and hence show reduced signaling (Burke et al. 
1999; Shirras 2000; Couso 2011). 
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4.1.1 Mechanism of Hh Signal Transduction 
 
The canonical Hh signaling cascade is initiated in the target cell upon binding of the Hh 
ligands to 12-span transmembrane receptors, encoded by the genes PTCH1 and PTCH2 
(Hooper and Scott 1989; Nakano et al. 1989; Goodrich et al. 1996). Two hydrophilic 
extracellular loops are displayed by these receptors which mediate the ligand interactions 
(van den Brink 2007). Ptch family members and bacterial transport proteins share extensive 
homology. These proteins belong to the Resistance-nodulation-cell division (RND) family 
and involved in the transport of various substrates across the cell membrane (Hausmann 
et al. 2009). The eukaryotic Ptch superfamily includes Dispatched (Disp) which maintains 
the discharge of Hh proteins and Niemann-Pick C1 protein (NPC1) regulating cholesterol 
homeostasis (Hausmann et al. 2009).  
 
The Hh reception by Ptch is enhanced by the presence of several other Hh binding proteins 
at the cell surface. These additional co-receptors such as, fibronectin type III (FnIII), and 
immunoglobulin family of membrane proteins Ihog (Interference hedgehog) and Boi 
(Brother of Ihog) transmembrane proteins in Drosophila and Cdo (Cell adhesion molecule 
related/downregulated by oncogenes) and  Boc (Brother of Cdo) in vertebrates are encoded 
by cell surface Ig/fibronectin and are the closest mammalian relatives of Drosophila  Ihog, 
and Gas1 (growth arrest-specific gene 1), act as a specific surface protein and binds SHH 
for signaling (Tenzen et al. 2006; Kang et al. 2007; Beachy et al. 2010; Camp et al. 2010; 
Izzi et al. 2011). Another Hh binding protein in vertebrates is HIP (hedgehog interacting 
protein) a membrane glycoprotein binding to three Hh proteins with an affinity comparable 
to Ptch1 (Chuang et al. 2003; Bosanac et al. 2009b). 
 
The Hh signaling cascade involves a dual function of Ptch1, as a receptor of Hh ligand and 
as a negative regulator of the pathway, by inhibiting the G protein-coupled receptor (GPCR) 
like signal transducer Smoothened (SMO) (7-pass transmembrane protein) in the non-
motile primary cilium (PC), where Ptch localizes in the absence of the Hh ligand (Taipale et 
al. 2002; Eggenschwiler and Anderson 2007; Rohatgi et al. 2007; Roberts et al. 2016). The 
primary cilium, a microtubule-based organelle, which protrudes from the cell surface of most 
vertebrate cells, is a requisite for Hh signal transduction (Goetz and Anderson 2010).  
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Smoothened is a member of the Frizzled family (class F) of GPCRs and contains an N-
terminal, ~14 kDa extracellular cysteine-rich domain (CRD), connected with a linker to a 7-
span transmembrane (7TM) protein and an extended C-terminal tail (Ruiz-Gómez et al. 
2007). Small molecule inhibitors are believed to play an important role in understanding the 
mechanism by which Ptch represses the pathway, by inhibiting smoothened SMO 
regulation. This was clarified when, there were reports showing, oxysterols, oxidized 
derivatives of cholesterol, bind specifically to Smo CRD and hence activate the Hh signaling 
pathway (Rana et al. 2013; McCabe and Leahy 2015). Various smoothened antagonists, 
targeting the heptahelical bundle domain of SMO, have also worked in favor of this 
assumption. These antagonists functionally mimic the overexpression of Ptch (Chen et al. 
2002; Frank-Kamenetsky et al. 2002; Taipale et al. 2002). Recent reports have also shown 
that Hh signal transduction modulates cholesterylation of SMO, and thereby making SMO 
cholesterylation, a therapeutic target to treat Hh pathway related cancers (Xiao et al. 2017). 
 
Gli zinc finger transcription factors mediate Hh signaling at the distal end of the pathway. 
Cubitus interruptus (Ci) is the Gli homolog in Drosophila and in vertebrates there are three 
different Gli transcription factors, GLI1, GLI2 and GLI3 (Hui and Angers 2011). In mammals, 
Gli1, Gli2 and Gli3 contain a carboxy-terminal activation domain but only Gli2 and Gli3 have 
N-terminal repressor domains (Dai et al. 1999; Sasaki et al. 1999). In the absence of the 
Hh ligands, Ci and Gli2/3 are proteolytically processed into repressor forms by removal of 
the activation domain (Aza-Blanc et al. 1997; Hsia et al. 2015). Hh regulated proteolytic 
processing of Ci, Gli2 and Gli3 is promoted by Protein Kinase A (PKA), Casein Kinase1 
(CK1) and Glycogen Synthase Kinase 3β (GSK3β), leading to binding of an E3 ubiquitin 
ligase complex containing β-TrCP (in mammals), and hence proteasome-mediated 
digestion (Jiang 2006; Marks and Kalderon 2011). Albeit myriad facets of vertebrate GLI-R 
production remain elusive, KIF7 (Kinesin family member 7), Suppressor of Fused (SuFu) 
and the primary cilium are needed for adequate processing of GLI-FL (full length) into GLI-
R (repressor) (Cheung et al. 2009; Liem et al. 2009; Goetz and Anderson 2010). 
 
SuFu plays a vital role in the stabilization of GLI2/3 FL , retaining them in the cytoplasm and 
hence preventing their activation by nuclear translocation (Humke et al. 2010; Tukachinsky 
et al. 2010). When SuFu is absent GLI2-FL translocate to the nucleus and is converted into 
its activator form, GLI2-A (proteolytically processed) which is labile and rapidly degraded 
by cullin-3-based ubiquitin ligase adaptor SPOP  (Chen et al. 2009; Wang et al. 2010; Jin 
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et al. 2016). Apart from SuFu, KIF7 plays an important role in GLI processing, although the 
exact mechanism is unclear it is thought to recruit PKA, GSK3 and CK1 thereby 
phosphorylating GLI-FL (Ryan and Chiang 2012). 
 
Another important player in the Hh pathway is the G-protein-coupled-receptor Gpr161. It 
plays an essential role in Hh signaling by negatively regulating the pathway by determining 
Gli processing via cAMP signaling. The IFT-A  complex and Tulp3  are involved in trafficking 
of Gpr161 to the primary cilia (Pal and Mukhopadhyay 2015). Gpr161 is mostly expressed 
in neural tube development and is localized in nervous system post mid-gestation period. 
Localization of Gpr161 has also been found in cilia and the ciliary localization is perturbed 
upon knockdown of Tulp3 and IFT-A complex in these fibroblasts (Mukhopadhyay and 
Rohatgi 2014). GPR161 double knockout mutants have shown Gli3 processing defects, 
which are cilia dependent and Smo independent, implying GPR161 would affect Gli3 
processing. The phenotypic appearance of Gpr161 is like that of SuFu and PKA mutants. It 
has been shown that Sufu effects on the Hh pathway take place independent of primary 
cilia (Chen et al. 2009; Humke et al. 2010; Zeng et al. 2011), which indicates that Gli3 
processing by Gpr161 is modulated via activation of PKA. In the absence of Shh, GPR161 
is localized to primary cilium and promotes the increase in the levels of cAMP-mediated 
Gαs activation of adenylyl cyclase. In the presence of the ligand, Gpr161 moves away from 
the primary cilium preventing cAMP production and leading to pathway activation 
(Mukhopadhyay et al. 2013; Pal et al. 2016). 
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Figure1: The mammalian Hh signaling pathway. (a) In the absence of Hh ligand, the Hh receptor 
Patched (Ptch1) inhibits the accumulation of the signal transducer, Smoothened (Smo), on the ciliary 
membrane. As a result, at the base of the primary cilium, PKA and Kif7 promote proteolytic 
processing of the transcription factor Gli3 by the proteasome into a repressor form (GliR) that 
suppresses Hh target gene expression in the nucleus. In addition, Sufu stabilizes the Gli proteins 
and inhibits the transcriptional activity of Gli2, while PKA prohibits the accumulation of full-length Gli2 
(GliFL) in the cilium. All of these events ensure silencing of the Hh pathway without the ligand. (b) 
The Hh ligand binds to its receptor Ptch1 and co-receptors Boc/Cdon. Ptch1 is internalized with Hh, 
relieving the inhibition on Smo. Smo accumulates in the ciliary membrane through both lateral 
transport and the secretory pathways. Phosphorylation of Smo, for instance, at the EvC zone in 
osteoblasts leads to its dimerization and activation. This, in turn, abrogates PKA function and 
promotes the movement of Sufu–Gli2/3 complexes and Kif7 to the ciliary tip and perhaps dissociation 
of Gli2/3 from Sufu in this process. Kif7 also facilitates the trafficking of Gli2/3 into the cilium (e.g. in 
chondrocytes). Accumulation of Gli2/3 at the ciliary tip is associated with the production of Gli 
activators (GliA), which are derived from the full-length Gli proteins. Accumulation of GliA to the 
nucleus enables activation of Hh target genes such as Ptch1, Gli1, and Hhip1 (Nozawa et al. 2013).  
 
4.1.2 Hh Signaling and Cancer 
 
The Hedgehog signaling pathway is essential for embryonic development and stem cell 
maintenance (Wu et al. 2017). But, aberrant activation of the pathway is also linked to 
various forms of cancer. Medulloblastoma (MB), basal cell carcinoma (BCC), 
rhabdomyosarcoma (RMS) and several other forms of cancer have documented the roles 
of mutated Hh pathway components (Raffel et al. 1997; Xie et al. 1998; Tostar et al. 2006). 
In addition, tumor microenvironment modulation by Hh signaling has been shown to be a 
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prominent player in breast, lung, liver, stomach, pancreas, colon and prostate cancer 
(Berman et al. 2003; Thayer et al. 2003; Watkins et al. 2003; Karhadkar et al. 2004; Huang 
et al. 2006; Mukherjee et al. 2006; Varnat et al. 2009). In light of these reports, Hh signaling 
becomes very important for targeted cancer therapy.  
 
Three basic models of Hh pathway activation have been proposed (Rubin and de Sauvage 
2006). Type I cancers contain an activating mutation in the Hh pathway, independent of Hh 
ligand and therefore inhibitors should target at or below SMO in the Hh cascade to be 
therapeutically effective (Gupta et al. 2010b). Type II cancers are ligand-dependent and do 
not display any somatic mutations in the Hh pathway. An autocrine mode of Hh signaling 
occurs in these cancers where Hh is produced and also utilized by the same cells or 
neighboring tumor cells. SMO antagonists can inhibit autocrine Hh signaling in these tumors 
(Gupta et al. 2010b). Type III cancers are also ligand-dependent but in these tumors, 
paracrine signaling works, which is motivated by the overexpression of the Hh ligand by 
these tumors, which are received by the stromal cells and produce reciprocal signals 
leading to the growth and survival of tumors. A combination therapy targeting the Hh 
pathway in stromal cells and drugs for the tumor cells should be used to treat this kind of 
cancer (Gupta et al. 2010b). A variant of this type of cancer may be a reverse paracrine 
signaling, where the ligand is secreted by the stromal cells and received by the tumor cells 
for maintaining growth and survival. Till now this mode of signaling has only been observed 
in hematological malignancies like leukemia, lymphoma and multiple myeloma in which 
stromal secreted Hh is utilized by cancerous B-cells through upregulation of Bcl2, which is 
an antiapoptotic factor (Dierks et al. 2007; Scales and de Sauvage 2009; Gupta et al. 2010b; 
Abidi 2014). 
 
Therapeutically the Hh pathway is an important target for cancer and regenerative medicine. 
The primary focus has been to study the prominent role of Hh signaling in promoting cancer. 
Currently, vismodegib and sonidegib, which are SMO inhibitors are the only clinically 
approved treatments for metastatic BCC (Dlugosz et al. 2012; Burness 2015). Arsenic 
Trioxide (ATO), an FDA approved inhibitor of GLI1 and GLI2 transcription factors. ATO 
directly binds to GLI1 and GLI2, inhibiting activity and decreasing expression of canonical 
Shh-GLI genes. It is currently a part of several clinical trials for both solid tumors and 
hematological malignancies (Beauchamp et al. 2011; Amakye et al. 2013). Drug resistance 
and cross-resistance often follow the treatment with SMO antagonists (Atwood et al. 2013; 
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Sharpe et al. 2015; Danial et al. 2016). Four different acquired resistance mechanisms have 
been known. Type I is the resistance via mutations in SMO in metastatic medulloblastoma, 
which can be overcome by using SMO mutant, SMO translocation, and GLI inhibitors. Type 
II is the resistance to SMO inhibitor due to amplification of GLI2 in Ptch-mutant 
medulloblastoma mouse model, which can be overcome by the use of GLI1 inhibitors. Type 
III is the resistance by the upregulation of PI3K-mTOR pathway, where, use of PI3K-mTOR 
and GLI1 inhibitors would overcome the resistance. Type IV is the resistance by the  
upregulation of aPKCɩ/λ in human basal cell carcinoma, which could be overcome by the 
use of aPKCɩ/λ inhibitors. Apart from the different mechanisms of SMO inhibitor resistance, 
it would be quite informative and helpful to consider and investigate other pathways that are 
interacting with Shh signaling so that the components of these pathways can be used in the 
context of combination therapy (Huang and Yang 2015). 
 
4.2 Regulation of Hh signaling by Kinases 
 
Protein kinases have been known to modulate the Hh signaling which includes, PKA, PKC, 
GRK2, MEK, ERK, AKT, and GSK3β (Wang et al. 2000; Riobo et al. 2006; Lauth et al. 2007; 
Chen et al. 2011; Wang et al. 2012; Zhao et al. 2016). Recent studies have pointed towards 
the involvement of targeting different kinases and hence aiming for a specific response.  
 
Protein Kinase A (PKA) is known to play key roles in many biological processes. In Hh 
receptive cells, PKA is involved in fate specification and in proliferation by attenuating Hh 
signaling. When the Hh pathway is inactive, even basal levels of active PKA can repress 
the Hh target genes. The important substrates of PKA are the Ci/Gli family, which can 
activate and repress Hh target gene expression. The basal level of PKA activity in Hh-
responsive cells should be precisely regulated as increased and decreased levels of PKA 
activity would lead to cell proliferation negatively and can alter cell fate specification. 
However, the mechanism of PKA activity regulation is quite obscure, as its dependent on 
varying factors of different cell types, tissues, and organisms. Two different mechanisms 
have been proposed to address the mechanism; (1) activity of PKA is regulated by cAMP; 
(2) PKA activity is regulated by a protein known as Misty somites (Kotani 2012). PKA and 
CKI are involved in regulation of Smo accumulation at the cell surface in response to Hh. It 
has been shown in Drosophila wing disc, blockade of PKA and CKI leads to prevention of 
Smo accumulation upon Hh induction. Smo is phosphorylated by PKA and CKI at many 
 Introduction 
 
10 
sites and phosphorylation-defective mutants of Smo are unable to accumulate at the cell 
surface and poorly equipped to transduce Hh signals. At the same time, it has also been 
shown that variants of Smo mimicking phosphorylation exhibit continuous expression at the 
cell surface and also able to transduce signals (Jia et al. 2004). The PKC family of proteins 
consists of three groups: the calcium-dependent conventional PKC isoforms (α, βI, βII, and 
γ), the calcium-independent novel PKC isoforms (δ, ϵ, η, and θ), and the calcium-
independent atypical PKC isoforms (ζ, λ/ι) (Ron and Mochly-Rosen 1995; Brodie et al. 
2004). Protein Kinase C (PKC) pathways and Hh undergo complex crosstalk and PKCdelta 
has been shown to inhibits Gli protein transcriptional activity and thereby alter Hedgehog 
signaling and negatively affect tumorigenesis in Hh associated cancers (Cai et al. 2009b). 
Reports have also shown, Ras-independent activation of MAPK/ERK kinase (MEK) and 
extracellular signal-regulated kinase (ERK) pathway by PKCdelta (Ueda et al. 1996). And 
oncogenic KRAS through RAF MEK/MAPK signaling has been shown to be directly involved 
in the activation of the hedgehog pathway in pancreatic ductal adenocarcinoma (PDA) cells 
and the crosstalk between two pathways play a significant role in PDA progression (Ji et al. 
2007). In general, the kinases in the CMGC (CDKs, MAPKs, GSK3s, CLKs) group have a 
broad spectrum of functional roles ranging from signal transduction to cell cycle regulation, 
RNA related processing, and intracellular communication (Varjosalo et al. 2013). Less 
studied candidates include the dual-specificity tyrosine regulated kinases (DYRKs) and the 
serine-arginine protein kinases (SRPK) (Singh and Lauth 2017). Dual specificity tyrosine 
phosphorylation regulated kinases (DYRKs) have shown to positively and negatively 
regulate Hh signaling pathway. (Mao et al. 2002; Shimokawa et al. 2008; Varjosalo et al. 
2008; Lauth et al. 2010; Keramati et al. 2014b; Schneider et al. 2015a; Gruber et al. 2016; 
Singh et al. 2017). 
 
4.2.1 Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) 
 
The first member of the DYRK family to be discovered was YAK1 from budding yeast 
(Garrett and Broach 1989; Soppa and Becker 2015). DYRK family members have a 
characteristic sequence motif called the DYRK-homology box (DH box) (Figure 2). The 
mammalian DYRK subfamily is comprised of five members and they are categorized into 
two classes. This categorization is based on the sequence homologies within the conserved 
kinase domain (Becker et al. 1998; Aranda et al. 2011). Class I consists of DYRK1A and 
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DYRK1B (the latter is also known as a Minibrain-related kinase (Mirk)), whereas class II is 
made up of DYRK2, DYRK3, and DYRK4 (Becker et al. 1998; Soppa and Becker 2015).  
 
Class I DYRK have certain distinct sequence motifs, such as a C-terminal PEST domain (a 
region rich in proline (P), glutamic acid (E), serine (S), and threonine (T)), which functions 
as a signal for rapid protein degradation (Figure 2) (Galceran et al. 2003). DYRK1A contains 
a poly-histidine stretch (13 consecutive histidine residues) and a serine/threonine enriched 
region (S/T-rich region) (Alvarez et al. 2003; Park et al. 2009). The poly-histidine stretch 
promotes the targeting of DYRK1A to nuclear speckles which are enriched with pre-mRNA 
splicing factors regulating the splicing machinery (Alvarez et al. 2003; Salichs et al. 2009). 
Class II DYRK kinases contain an N-terminal auto-phosphorylation accessory region 
(NAPA) domain, which is required for tyrosine auto-phosphorylation specifically in class II 
DYRKs. The NAPA domain in DYRK2 has been shown to autophosphorylate itself under in 
vitro conditions (Lochhead et al. 2005; Kinstrie et al. 2010; Aranda et al. 2011; Walte et al. 
2013). 
 
DYRK family members regulate protein stability, cell proliferation, and differentiation by 
phosphorylating DYRK recognition sites in target proteins. The consensus sequence motif 
consists of Ser or Thr followed by Pro in position +1. Furthermore, an arginine residue at 
position −2 or −3 relative to Ser/Thr seems to be preferred (RxxS/TP or RPxS/TP), although 
a considerable degree of divergence to this consensus has also been noted (Aranda et al. 
2011; Soundararajan et al. 2013). 
 
DYRK kinases contain an activation loop with a conserved YXY sequence, the 
phosphorylation of which leads to the activation of full enzymatic activity. Due to the distinct 
ability of DYRK family members to auto-phosphorylate the second tyrosine residue in order 
to be fully activated and then phosphorylate substrates in trans on Ser/Thr residues, they 
are known as Dual-specificity tyrosine-regulated kinases (Aranda et al. 2011; 
Soundararajan et al. 2013; Soppa and Becker 2015). The auto-activation mode by an 
upstream kinase is needed for the phosphorylation of the activation loop in case of MAP 
kinase, which is in contrast to DYRKs (Aranda et al. 2011). The tyrosine specificity of 
DYRKs is lost after the protein translation and the Ser/Thr specificity on target proteins 
remains (Lochhead et al. 2005; Alvarez et al. 2007). 
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or cells derived from Down syndrome patients have shown that the increased expression 
of DYRK1A kinase affects neurogenesis and neuroblast proliferation, and results in 
impaired behavioral phenotypes (Contestabile et al. 2007). Behavioral and cognitive 
impairment and neuronal alterations in mice have been shown due to overexpression of 
DYRK1A (Martinez de Lagran et al. 2004; Dierssen 2012; Thomazeau et al. 2014). In 
contrast, a significant decrease in brain size in mice, flies, and men has been shown due to 
loss of function of Dyrk1A or mnb (Tejedor et al. 1995; Moller et al. 2008; Tejedor and 
Hammerle 2010; van Bon et al. 2016). 
 
Studies on DYRK1A/mnb have shown that these kinases play an important role in the 
development of the central nervous system (Tejedor et al. 1995). The Hh signaling pathway 
also plays a significant role in neuronal proliferation (Ruiz i Altaba 1999). Mitogenic roles 
for SHH in neuronal precursor cells, in the cerebellum, neural tube and spinal cord have 
been reported (Rowitch et al. 1999; Wechsler-Reya and Scott 1999). Loss of function 
mutations in Patched which leads to the aberrant activation of HH signaling also leads to 
the proliferation of neural precursors (Wechsler-Reya and Scott 1999). As there have been 
a lot of parallel effects of Shh and DYRK1A, a plausible interaction of these pathways in 
neural development is foreseen.  
 
GLI1 has been found to be one of the downstream targets of DYRK1A. Researchers have 
shown that the nuclear translocation and function of Gli1, an oncogenic transcription factor 
is mediated by DYRK1A through phosphorylation of nuclear localization signals located in 
the N-terminus of Gli1 (Pusapati et al. 2018). DYRK1A can retain Gli1 in the nucleus and 
regulate its transcription (Mao et al. 2002). DYRK1A can also dissociate the Suppressor of 
Fused (SuFu) (a negative regulator of Hh signaling) and Gli complex independent of the N-
terminal phosphorylation of Gli1 (Schneider et al. 2015a). Several reports have suggested 
reduced Hh activity in DS patients, (Roper et al. 2006) which is paradoxical as per the 
hypothesis in which DYRK1A stimulates Hh pathway in a positive manner (Currier et al. 
2012; Das et al. 2013). To support this argument, levels of Hh target genes have been 
compared between normal brain and the brains of DS patients and a significant reduction 
in the expression level was seen (Lockstone et al. 2007). Mechanistic studies revealed that 
DYRK1A regulates the actin cytoskeleton (Liu et al. 2009; Park et al. 2012; Schneider et al. 
2015a) by functional inactivation of actin binding LIM protein (ABLIM). Novel DYRK1A 
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phosphorylation targets i.e. ABLIM proteins, (Schneider et al. 2015a) have been elucidated 
while confirming the negative regulation of Hh pathway by DYRK1A kinase. 
 
DYRK1B Kinase: 
 
The closest relative of mammalian DYRK1A is the DYRK1B kinase, also referred to as 
MIRK (Minibrain-related kinase). DYRK1B was cloned independently by two groups. One 
of the research groups performed RACE studies on human testis RNA (Leder et al. 1999a) 
and another group from a colon carcinoma cell line (Mercer and Friedman 2006b). DYRK1B 
is located on the 19q13.2 chromosome. This region is often amplified in ovarian and 
pancreatic cancer (Jin et al. 2007; Davis et al. 2013). This kinase has three splice variants 
(DYRK1B-p65, DYRK1B-p69, and DYRK1B-p75) with varying expression patterns. 
DYRK1B-p65 and DYRK1B-p69, are differentially expressed in mouse tissues, spleen, 
lung, brain, bladder, stomach and testes whereas DYRK1B-p75 is specifically expressed in 
skeletal muscles and differentiated adipocytes. Transcripts containing either exon 1A or 
exon 1B encode these variants, due to the use of separate promotors which would explain 
the distinct pattern of expression of these variants (Leder et al. 2003). Human DYRK1A and 
DYRK1B proteins are 84% identical in the N-terminal and catalytic domains but show no 
extended similarity in the C-terminal domain. Human and mouse DYRK1B proteins share 
97% sequence similarity (Kentrup et al. 1996; Becker et al. 1998; Becker and Joost 1999; 
Leder et al. 1999b; Li et al. 2001). Similar to DYRK1A, DYRK1B also has an NLS sequence, 
a conserved kinase domain, a PEST sequence and a MAPK phosphorylation sequence in 
C-terminus (Leder et al. 1999a; Mercer and Friedman 2006b). DYRK1B has a similar 
activation mechanism as DYRK1A. DYRK1B has a limited expression in normal tissue, with 
highest expression seen in skeletal muscle, heart, testes, and brain (Lee et al. 2000). 
Myogenesis became the most studied model to elucidate the functions of the DYRK1B 
kinase (Lu et al. 2000; Deng et al. 2003; Mercer et al. 2005). This is due to the fact that 
differentiation can be followed biochemically by monitoring the expression of well-
characterized proteins. The protein levels of DYRK1B are low in the dividing myoblasts. 
During the differentiation phase, the levels of DYRK1B increase greatly and remain 
unchanged in the mature myoblasts. Mirk promotes myoblast differentiation indirectly by 
phosphorylating class II histone deacetylases, which in turn accumulate in the cytoplasm 
and thereby suppression of myogenin-dependent transcription is relieved (Deng et al. 
2005). Mirk promotes the survival of differentiating myoblasts by phosphorylating the CDK 
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inhibitor p21 and causing p21 to accumulate in the cytoplasm where it functions as an anti-
apoptotic signaling molecule (Mercer et al. 2005). These studies have helped to elucidate 
the role of DYRK1B as a multifunctional Ser/Thr kinase which plays critical roles in muscle 
differentiation by executing some regulatory effects on motility, transcription, cell cycle 
regulation and cell survival (Mercer and Friedman 2006a). 
  
DYRK1B phosphorylates and blocks degradation of the cyclin-dependent kinase (CDK) 
inhibitor p27 to maintain a quiescent state (Deng et al. 2014b). DYRK1B is highly abundant 
and active in normal diploid cells and in cancer cells transiently arrested in G0, or in early 
G1, with up to 10-fold lower levels in cycling cells (Deng et al. 2004). Mirk is known to be 
localized fast-twitch skeletal muscles and its inhibition leads to an increase in the amount 
of toxic ROS (Reactive Oxygen Species) induced in differentiating C2C12 myoblasts and 
postmitotic cultures of myotubes which lead to the formation of skeletal muscle. These 
muscles produce ROS endogenously during contractions. Cancer cells can regulate the 
elevated levels of ROS, which promotes many aspects of tumor development and 
progression by upregulating DYRK1B and amplifying DYRK1B gene (Deng et al. 2014b). 
DYRK1B has been shown to play an important role in breast cancer progression. Statistical 
analysis has shown that various clinicopathologic factors such as tumor size, grade, 
estrogen receptor status, Ki-67 (cellular marker of proliferation) expression are associated 
with the extent of expression of DYRK1B and overexpression results in poor prognosis. 
Also, DYRK1B has been shown to phosphorylate FoxO1 (Forkhead box protein O1) and 
hence promote its nuclear exclusion (Chen et al. 2017). FoxO1 is also subject to regulation 
by PI3K-AKT pathway, which phosphorylates and subsequently translocates FoxO1 out of 
the nucleus, suggesting the involvement of DYRK1B in the PI3K-AKT pathway (Bullock 
2016). Mirk activity also increases with the exposure to chemotherapeutic drugs such as 5-
FU or cisplatin (Jin et al. 2009; Hu and Friedman 2010), through stress signaling to the 
DYRK1B kinase activator MAPK kinase MKK3 (Lim et al. 2002). Recent reports have 
demonstrated that phosphorylation of S471 (site for DYRK1B autophosphorylation) 
contribute to DYRK1B kinase activity. Also, DYRK1B has been defined as a new substrate 
of ERK1/2 signaling. The ERK1/2 pathway is a key regulator of the cell cycle, promoting 
proliferation or cell cycle arrest (Ashford et al. 2016). Mirk is upregulated and amplified in 
the majority of pancreatic and ovarian cancers (Friedman 2007). Mirk has antiapoptotic 
functions in cancer cells in which Mirk is highly expressed such as rhabdomyosarcoma cells 
(Mercer et al. 2006), colon carcinoma cells (Lee et al. 2000), and HeLa cervical carcinoma 
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cells (MacKeigan et al. 2005). RNAi mediated knockdown of Mirk has shown to reduce the 
clonogenicity of pancreatic cancer cells and reducing the tumor cell number, which shows 
that Mirk mediates survival in these cells (Deng et al. 2006). Mirk knockout or depletion had 
no detectable effect on normal tissue which indicates a selective effect of Mirk kinase 
inhibitor on cancer cells expressing elevated levels of Mirk kinase (Ewton et al. 2011). 
Functional characterization of the DYRK1B gene revealed that the nonmutant protein 
inhibited the SHH and WNT pathways, thereby enhancing adipogenesis (Keramati et al. 
2014a). The DYRK1B locus on 19q13 has been linked to type 2 diabetes (Cho et al. 2011) 
and is shown to play a central role in the altered pathways in metabolic syndrome (Keramati 
et al. 2014a). As there is a high abundance of DYRK1B in testes, one of the reports 
suggests that cold-inducible RNA-binding protein (Cirp) functions to positively affect the 
proliferation of undifferentiated spermatogonia by interacting with DYRK1B. Cirp modulates 
the protein levels of p27 and cyclinD1 by suppressing the kinase activity of DYRK1B and 
hence promoting the cell cycle progression of undifferentiated spermatogonia (Masuda et 
al. 2012). Adding up to the developmental roles of mirk, the zebrafish dyrk1b gene is shown 
to be important for the endoderm formation and craniofacial patterning (Mazmanian et al. 
2010).  
 
DYRK1B has been shown to positively and negatively affect Hh signaling (Singh et al. 
2017). It could activate PI3K/AKT/mTOR pathway, which is an established oncogenic driver 
in humans. This pathway has been well characterized and recognized to play essential roles 
in normal cellular functions including nutrition and energy balance, protein synthesis and 
growth control in mammalian cells, thereby, making DYRK1B an important target in Hh 
signaling pathway. 
 
4.2.3 Class II DYRKs 
 
DYRK2, DYRK3, and DYRK4 proteins contain a canonical kinase domain located between 
a large N-terminal region and a short C-terminal extension and features specific to DYRK 
related kinases. DYRK2 and DYRK4, but not DYRK3, possess an NLS sequence and all 
three contain a NAPA (N-terminal autophosphorylation accessory region) domain which is 
absent in class I DYRKs (Aranda et al. 2011; Singh and Lauth 2017). Despite lacking NLS, 
DYRK3 (also known as REDK) is localized in the nucleus in hematopoietic cells (Lord et al. 
2000) whereas DYRK2 is mostly cytosolic, but in conditions of genotoxic stress it 
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accumulates in the nucleus (Taira et al. 2007).  DYRK4 displays splice variant dependent 
subcellular localization (Aranda et al. 2011). DYRK2 shares 46% and DYRK3 shares 43% 
identity with class I DYRKs in the catalytic domain respectively but lack the striking 
sequence motifs such as a C-terminal PEST domain (Becker et al. 1998). Tyrosine 
autophosphorylation by class II DYRKs requires an N-terminal auto phosphorylation 
accessory region (NAPA) motif, which is present in the N-terminal region of class II DYRKs 
only (Aranda et al. 2011). This domain provides a chaperone-like function (Aranda et al. 
2011) and transiently converts class II DYRKs into intramolecular tyrosine kinases (Kinstrie 
et al. 2010).  
 
DYRK2 has been shown to phosphorylate very limited number of substrates such as 
NFAT4, eIFB5, Glycogen synthase6, Oma-17, MEI-18 and chromatin remodeling factors 
SNR1 and TRX9, hence regulating calcium signaling, protein synthesis, glucose 
metabolism, developmental processes and gene expression (Skurat and Dietrich 2004; 
Nishi and Lin 2005; Gwack et al. 2006; Kinstrie et al. 2006; Lu and Mains 2007; Maddika 
and Chen 2009). DYRK2 has also been shown to function in DNA damage signaling 
pathway (Taira et al. 2007). The role of DYRK2 in human cancer remains questionable. As, 
overexpression of DYRK2 predicts better survival in non-small cell lung cancer (NSCLC), 
breast cancer and pulmonary adenocarcinoma, implying a tumor suppressor role 
(Yamashita et al. 2009a; Yamashita et al. 2009b). On the other hand, there are reports 
showing, amplification of DYRK2 gene in esophageal/lung adenocarcinoma as well as in 
gastric stromal tumor implying its potential oncogenic role (Miller et al. 2003; Koon et al. 
2004; Yan et al. 2016).  
 
Signal transduction roles of DYRK3 have been reported, where DYRK3 has been shown to 
regulate raft-mediated endocytosis/caveolae which operate on the principles of membrane 
trafficking. Knockdown of DYRK3 strongly increased the dynamics of caveolar vesicles and 
had a minor destabilizing effect on the caveolar coat (Fujimoto et al. 2000; Pelkmans et al. 
2005; Tagawa et al. 2005). The kinase-dependent differential regulation of cycling events 
between the cell surface and intracellular organelles probably involve changes in the cortical 
actin cytoskeleton and activation of microtubule-dependent motility (Mundy et al. 2002; 
Pelkmans and Helenius 2003; Pelkmans et al. 2005). Integral roles of caveolin-1 have also 
been documented for sequestering the Hh receptor complex in cholesterol-rich 
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microdomains of the plasma membrane, which act as a scaffold for the interactions with the 
Hh protein (Karpen et al. 2001).  
 
DYRK4 is expressed in the testes of adults, but not prepubertal rats (Becker et al. 1998) 
and is highly restricted to step 8 spermatids (Sacher et al. 2007). DYRK4 was shown to be 
present in the duck ovary, and was more active or upregulated in the high egg production 
(HEP) ovaries, which would argue for its role in the female reproductive system but the 
underlying mechanism is still elusive (Tao et al. 2017).   
 
4.3 Hh Signaling & DYRK1B kinase 
 
The DYRK kinase family has a close regulatory connection to the Hh pathway with its five 
members DYRK1A, DYRK1B, DYRK2, DYRK3 and DYRK4 (Mao et al. 2002; Varjosalo et 
al. 2008; Lauth et al. 2010; Aranda et al. 2011; Schneider et al. 2015b; Gruber et al. 2016). 
In particular, DYRK1B (a.k.a. MIRK) is linked with several cancer types and is amplified or 
hyperactive in ovarian and in pancreatic cancer (Mercer et al. 2006; Friedman 2007; 
Friedman 2010b; Hu and Friedman 2010; Deng and Friedman 2014; Deng et al. 2014a). 
DYRK1B has been known to affect Hh signaling in both a positive and a negative manner. 
On the one side, DYRK1B dampens Hh signaling initiated by SMO (Lauth et al. 2010; Jacob 
et al. 2011; Keramati et al. 2014b), and on the other DYRK1B promotes the stability of GLI 
transcription factors (Gruber et al. 2016). DYRK1B has been shown to stabilize GLI1 
transcription factors by activating the pro-survival PI3K/mTOR/AKT arm, a positive regulator 
of Gli stability (Riobo et al. 2006; Fruman and Rommel 2014; Kern et al. 2015). Hh pathway 
stimulation leads to an increase in DYRK1B protein levels by currently unknown post-
transcriptional mechanisms suggesting a feedback loop (Singh et al. 2017). The Hh 
signaling has been known to have an inhibiting impact on adipocytic differentiation (Kha et 
al. 2004; Johnson et al. 2011; Nosavanh et al. 2015) whereas DYRK1B favors the in vitro 
differentiation into adipocytes (Keramati et al. 2014b). This is true for DYRK1B carrying 
mutations identified in families suffering from an autosomal dominant form of metabolic 
syndrome, a disease with prominent adipocytes involvement (Keramati et al. 2014b). 
Although the mechanistic and functional integration of DYRK1B with other signaling 
pathways is not elucidated, it's interesting to know that mutant DYRK1B expression reduced 
GLI2 levels in cultured adipocytes (Keramati et al. 2014b). Therefore, the involvement of 
Hh signaling can be speculated in these effects.  
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The cytoskeleton of eukaryotic cells is made up of filamentous protein, and it is known to 
provide mechanical support to the cell. Microtubules are the largest type of filament and 
they are composed of polymerized tubulin monomers. Tubulin contains two polypeptide 
subunits and dimers of these subunits come together to form long strands called 
protofilaments. Thirteen protofilaments come together to form long straw shaped 
microtubules. With addition and subtraction of tubulin dimers, microtubules are dynamic. In 
cells, microtubules are anchored to microtubule organization centers (MTOCs). The 
centrosome, basal bodies and spindle pole bodies are different forms of MTOCs. 
Microtubules tend to grow from the centrosome to the plasma membrane. In non-dividing 
cells, microtubules support the basic organization of the cytoplasm including the positioning 
of the organelles. Microtubules are responsible for organelle transport, mitosis, secretion, 
cell shape, polarization and cell migration. Various post-translational modification plays 
important roles in the regulation of microtubule function. Some of the examples include 
acetylation, phosphorylation, polyglycylation, and others (Westermann and Weber 2003; 
Janke and Bulinski 2011; Janke 2014).  
 
One of the best-studied covalent modification is acetylation, which is associated with stable 
microtubules e.g. in primary cilia and is conserved from protists to humans. Acetylation 
occurs on Lys40 of the α-subunit of the α/β-heterodimer within microtubules. Functionally, 
microtubules facilitate the transport along their tracks by binding to specific motor proteins 
(Reed et al. 2006; Cai et al. 2009a; Hammond et al. 2010; Walter et al. 2012). Increased 
tubulin acetylation has been shown to promote MT-directed mitochondrial transport in 
neurons (Chen et al. 2010) and to compensate for vesicular transport deficits in a cellular 
model of Huntington’s disease (Dompierre et al. 2007). MT acetylation is mainly governed 
by the opposite action of α-tubulin acetyltransferase 1 (ATAT, a.k.a. αTAT1 or MEC17), 
histone deacetylase 6 (HDAC6), and sirtuins2 (SIRT2) which add or remove acetyl groups 
from α-tubulin, respectively (Hubbert et al. 2002; Montagnac et al. 2013). Abnormal levels 
of this modification are linked to neurological disorders, cancer, heart disease, and other 
pathological diseases thereby making it therapeutically important (Singh et al. 2010; Di 
Martile et al. 2016; Stram et al. 2017; Tapias and Wang 2017). HDAC6 is a multifunctional 
protein with sequence homology to nuclear HDACs, and its involvement in the deacetylation 
of many non-histone proteins including tubulin (Li et al. 2012). It is involved in a wide variety 
of cellular processes including signal transduction, aggresome formation, stress granule 
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biology and gene transcription (Kawaguchi et al. 2003; Boyault et al. 2007; Kwon et al. 
2007; Shan et al. 2008; Deribe et al. 2009; Mak et al. 2012; Chen et al. 2013; Dhanyamraju 
et al. 2014). 
  
Although a lot is known about the enzymes regulating tubulin acetylation and different 
posttranslational modifications, very little is known about different signaling pathways and 
their effect on cytoskeletal regulation. The noncanonical Hedgehog signaling pathway has 
been known to modulate cytoskeletal remodeling (Brennan et al. 2012). While Hh signaling 
has been shown to affect the actin cytoskeleton (Bijlsma et al. 2007; Xiao et al. 2010; 
Schneider et al. 2015a), very little is known about its effects on MTs. 
 
In this work, I have shown that activated Hh signaling promotes MT acetylation, cell 
polarization and organelle transport such as MT-dependent mitochondrial transport. 
Furthermore, I have shown DYRK1B, whose levels are elevated by activated Hh signaling, 
can also affect tubulin acetylation positively. Supporting my findings, I have also shown that 
overexpression of DYRK1B leads to reduced HDAC6 activity. Also, my results have shown 
that increased DYRK1B levels inactivate Glycogen synthase kinase 3β (GSK3β) through 
Ser9 phosphorylation, resulting in HDAC6 inhibition and increased tubulin acetylation. In 
summary, using Hh signaling as a paradigm, I describe a mechanistic framework how 
intercellular communication can affect cytoskeletal regulation and cell function.  
 
4.4 Aim of the present work 
 
Hedgehog (Hh) signaling cascade is one of the intricate signal transduction mechanisms 
that govern the precisely regulated developmental processes of multicellular organisms. Hh 
has been shown to regulate actin cytoskeleton but not much is known about its regulation 
of MT cytoskeleton. Reports have also shown that Hh ligands promote the phosphorylation 
and activation of mTOR and AKT kinases. As protein kinases are known to play a significant 
role in Hh signal transduction, I have focused my research on DYRK1B kinase, a member 
of DYRK family of kinases which, possesses both serine/threonine and tyrosine kinase 
activities and enhances the transcriptional activity of TCF1/HNF1A. 
The aim of my present work is to elucidate the mechanistic regulation of Hh driven/mediated 
processes of mTOR/AKT activation and regulation of  MT cytoskeleton and MT-dependent 
processes with the DYRK1B kinase. 
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5 Results 
 
5.1 DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling 
through activation of the mTOR/AKT pathway 
Rajeev Singh, Pavan Kumar Dhanyamraju, Matthias Lauth 
 
Hedgehog ligands promote the stimulation of Gli transcription factors and also promote the 
phosphorylation and activation of mTOR and Akt kinases, although the molecular 
mechanism behind this unknown (Riobo et al. 2006; Wang et al. 2012). With my results, I 
have tried to place DYRK1B as a mediator between Hh signaling and mTOR/AKT activation. 
My work has shown, how DYRK1B negatively and positively affects Hh signaling. I have 
targeted DYRK1B in GLI dependent cancer cells, therapeutically by combining a DYRK1B 
antagonist with a mTOR/AKT inhibitor resulting in a strong GLI targeting and increased 
cytotoxicity in pancreatic and ovarian cancer cells.  
 
To identify the role of the DYRK1B kinase as a positive and negative modulator of 
Hedgehog signaling, I have used the RNAi technique where I knocked down DYRK1B in 
mouse embryonic fibroblasts stably expressing Sonic Hh ligand (MEF[SHH] cells) (Lipinski et 
al. 2008)), which renders these cells constitutively signaling. In figure 1A, siRNA knockdown 
of endogenous Dyrk1b led to an upregulation of several Hh target genes (Gli1, Ptch1, 
Ptch2) when compared to control siRNA-transfected cells. A de-repression of Hh pathway 
activity upon Dyrk1b knock-down was confirmed by measuring the protein levels of GLI1 
(Fig. 1A inset). Elucidating the roles of DYRK1B kinase when overexpressed, I treated 
NIH3T3 fibroblasts, stably transfected with empty control plasmid and V5-tagged DYRK1B 
(NIH[Con] and NIH[1B] cells; Fig. 1C) with the synthetic SMO agonist SAG (Chen et al. 2002) 
in order to stimulate membrane signaling. Immunoblotting for the endogenous GLI1 protein 
revealed that the DYRK1B-overexpressing cells had lost their SAG-responsiveness (Fig. 
1D, E), arguing that DYRK1B prevents Hh canonical signaling. However, the basal levels 
of GLI1 were increased in NIH[1B] cells even in the absence of any stimulatory SAG, 
indicative of a non-canonical activation of GLI activation. Furthermore, a 130 kDa isoform 
of GLI1 was seen in control cells, which was not evident in 1B overexpressing cells (Fig. 
1D). A 100 kDa large GLI1 isoform has previously been proposed to represent an inhibitory 
variant of GLI1 (Stecca and Ruiz i Altaba 2009). My results were further strengthened with 
the measurement of mRNA expression levels of target genes, where DYRK1B 
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overexpression blocked SAG-induced Hh signaling while at the same time it increased the 
basal expression of Ptch1 (Fig. 1F). Taken together, my data suggests that DYRK1B inhibits 
canonical Hh signaling while it promotes non-canonical activation of the GLI1 transcription 
factor.  
 
To support my results further I took human cancer cells (HeLa). Stable expression of 
DYRK1B increased the endogenous GLI1 protein levels (Fig. 2A) while at the same time it 
decreased the GLI1 mRNA levels (Fig. 2B). This ambiguity argued for a stabilizing effect of 
DYRK1B on the GLI1 protein. Protein stability assays were performed in NIH[Con] and NIH[1B] 
cells blocking de novo protein synthesis with Cycloheximide. Endogenous GLI1 got 
degraded with a half-time (t1/2) of approx. 3.5 h in SAG-treated control cells whereas GLI1 
protein levels in SAG-treated DYRK1B-expressing cells were extremely stable (Fig 2C,2D). 
As its already known that AKT kinase has a stabilizing effect on GLI transcription factors 
(Riobo et al. 2006; Paul et al. 2013; Shi et al. 2015), I treated the NIH[1B] cells, with a pan-
AKT inhibitor (GSK-690693) and GLI1 levels dropped significantly upon AKT inhibition, and 
could be rescued by pharmacological blockade of the proteasome (Fig. 2E). This proves 
that AKT mediated GLI protein stability is increased by ectopically expressed DYRK1B 
kinase.  
 
Following up on the results, I wanted to find out if DYRK1B could activate the 
PI3K/mTOR/AKT pathway. In line with my previous findings, overexpression of DYRK1B 
leads to the phosphorylation (activation) of mTOR (Ser2448) and AKT (Ser473 and Thr308) 
(Fig. 3A, B). As, AKTSer473 phosphorylation is mTORC2 dependent (Guertin et al. 2006; 
Shiota et al. 2006), and AKTTh308 phosphorylation is PDK-1 induced, my data suggests that 
DYRK1B directly or indirectly activates the PI3K/mTORC2/AKT signaling arm or that both 
phospho-sites communicate and influence each other. To investigate further, I looked at the 
phosphorylation status of downstream effectors of the second mTOR complex (mTORC1), 
which is S6-Kinase (S6K-Thr389) and the S6K target ribosomal protein S6 (S6-
Ser235/Ser236). Both S6K and S6 were phosphorylated (activated), hence suggesting that 
DYRK1B activates mTORC1 complex. Although in high serum conditions, the 
phosphorylation events were less evident. (Fig. 3C, D). DYRK1B-expressing HeLa cells 
also showed similar results as the fibroblasts (Fig. 2A) for AKT and mTOR phosphorylation. 
My results were further strengthened by using cells which are genetically depleted of 
DYRK1B through CRISPR/Cas9 methodology (Fig. 3E). These are mammalian HAP1 cells 
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harboring a haploid genome (Carette et al. 2011). Interestingly, DYRK1B-knock out (KO) 
cells displayed similar results as fibroblasts and HeLa cells i.e. reduced endogenous GLI1 
protein levels (Fig. 3E) and an overall reduced level of AKT (Ser473; Thr308) and mTOR 
(Ser2448) phosphorylation (Fig. 3F, G, and H). Taken together, my data implies that 
DYRK1B is an activator of the PI3K/mTOR/AKT signaling pathway. 
 
With my results from MEF[SHH] cells, where signaling is continuously active I could show 
elevated levels of phosphorylated AKT and mTOR, which could be suppressed by inhibition 
of the Hh pathway with the SMO antagonist SANT (Fig. 4A, B) (Chen et al. 2002). As 
DYRK1B has been shown to activate the mTOR/AKT kinases, there is a strong possibility 
of DYRK1B mediating the effects of Hh signaling on AKT/mTOR. Two different fibroblast 
cell lines have shown the induction of DYRK1B levels with Hh pathway stimulation and 
reduced DYRK1B levels with suppressed Hh signaling (Fig. 4C). Therefore, I analyzed the 
effect of Dyrk1b knock-down on phospho-mTOR/AKT levels in MEF [SHH] cells. As can be 
seen in figures 4D and 4E, the levels of phospho-AKTSer473 and phospho-AKTThr308 were 
significantly reduced upon knock-down of Dyrk1b. Thereby, I could say that DYRK1B 
mediates the effect of Hh signaling on phosphorylation of AKT (and potentially mTOR).  
 
The PI3K/mTOR/AKT system is subject to intense feed-back regulation. I investigated the 
systemic feedback regulation by analyzing AKT phosphorylation in NIH [MCS] and NIH[1B] cells 
upon inhibition of AKT (GSK-690693, a pan-AKT inhibitor), mTOR (KU-0063794, a dual 
mTORC1/2 inhibitor) and DYRK1B (AZ191, a selective small molecule DYRK1B inhibitor 
(Ashford et al. 2014)). As can be seen in figure 5A, all inhibitors led to a subsequent increase 
in phospho-AKT levels in DYRK1B-overexpressing cells, although they were different in 
amplitude. In contrast, in wild-type, NIH[MCS] cells, AKT, and mTOR inhibition resulted in 
reduced phospho-AKT levels while AZ191 led to an increase. Taken together with the 
previous experiments, this result strongly suggested that DYRK1B is indeed involved in a 
complex regulatory mTOR/AKT feedback loop.  To investigate further, ShhL2 cells (a clonal 
NIH3T3 cell line harboring a Hh/GLI-responsive luciferase reporter construct in the genome 
(Taipale et al. 2000)) were used. Hh activation by SAG and AZ191 was added for different 
time periods and the activity of Hh signaling was recorded. As can be seen in figure 5B and 
5C, when compared to the DMSO control, Hh signaling was suppressed by AZ191 in the 
first 24h and was then increased over controls at later time points (48-72h), suggesting a 
pronounced influence of feedback regulation on the kinetics of the Hh response. These data 
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show that the exact time point of analysis is important when determining the effects of 
DYRK1B. To delve deeper into the kinetics issue endogenous DYRK1B was knocked down 
in human Panc1 pancreatic cancer cells by two different approaches: 1.) In a short-term 
experiment (2-3d), short-interfering RNA (siRNA) was used and 2.) In a long-term 
experiment (6-7d), short hairpin RNA (shRNA) was applied. The acute knock-down of 
DYRK1B by means of siRNA (short-term) resulted in an increase of endogenous GLI1 
levels (Fig. 5D). In contrast, the long-term knock-down of DYRK1B through a shRNA 
approach led to a suppression of GLI1 expression (Fig. 5E). To rule out potential effects of 
siRNA versus shRNA technology, I performed a time course experiment treating Panc1 
cells for 9 d with AZ191 and determined the daily changes in GLI1 levels (Fig. 5F). 
Supporting my previous results, GLI1 protein levels were induced during the first 6 days, 
followed by a reduction afterward (7-9 d). Altogether, a prominent time-dependent impact 
of DYRK1B inhibition on GLI1 levels was seen.   
 
Considering that the fluctuating kinetics could lead to upregulation of oncogenic GLI1 levels 
in cancer cells, with short-term treatments with DYRK1B antagonists. I, therefore, tested 
the combination of AZ191 (DYRK1B inhibitor) with drugs targeting mTORC1/2 (KU-
0063794), AKT (GSK-690693) or S6K (PF-4708671) and measured the effects on GLI1 
levels in DYRK1B-amplified Panc1 cells (Fig. 6A). Treatment with AZ191 alone (24h) 
increased the phosphorylation of AKT and the GLI1 expression, whereas co-treatment with 
the mTOR/AKT/S6K inhibitors significantly reduced the levels of both. In combination with 
AZ191 however, GLI1 levels were almost completely abrogated (Fig. 6A). To measure the 
cytotoxic effects of these inhibitors, I performed cell growth assays. While single treatment 
with AZ191, KU-0063794, AKT inhibitor and S6K inhibitor alone displayed only a moderate 
effect on cell growth (cytostatic), the combination of drugs was strongly cytotoxic to 
pancreatic cancer cells (Fig. 6B, 6C, 6D). Moreover, the results on dual DYRK1B - 
PI3K/AKT/mTOR/S6 inhibition was not specific to Panc1 cells as I could reproduce them in 
Ovcar-3 ovarian cancer cells using combinations of AZ191 and inhibitors targeting PI3K, 
mTOR, AKT, and S6K. This concludes that a dual targeting approach combining a DYRK1B 
antagonist with an inhibitor of the PI3K/mTOR/AKT pathway has a pronounced impact on 
the GLI1 oncoprotein and exerts strong cytotoxic effects in cancer cells. 
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5.2 DYRK1B regulates Hedgehog-induced microtubule acetylation  
Rajeev Singh, Philipp Simon Holz, Katrin Roth, Anna Hupfer, Wolfgang Meissner, Rolf Müller, 
Malte Buchholz, Thomas M. Gress, Hans-Peter Elsässer, Ralf Jacob, Matthias Lauth 
 
The post-translational modifications (PTM) of tubulin subunits are important for maintaining 
the physiological functions of the microtubule (MT) cytoskeleton. A lot of progress has been 
made in the identification of enzymes carrying out MT-PTMs although little is known on how 
intercellular signaling molecules and their associated pathways regulate MT-PTM-
dependent processes inside signal-receiving cells. Here I show that Hedgehog (Hh) 
signaling, affects the MT acetylation in mammalian cells. Mechanistically, Hh pathway 
activity increases the levels of the MT-associated DYRK1B kinase, resulting in the inhibition 
of GSK3β through phosphorylation of Serine 9 and the subsequent suppression of HDAC6 
enzyme activity. Since HDAC6 represents a major tubulin deacetylase, its inhibition 
increases the levels of acetylated MTs. Through the activation of DYRK1B, Hh signaling 
facilitates MT-dependent processes such as intracellular mitochondrial transport, 
mesenchymal cell polarization or directed cell migration. Taken together, my results provide 
evidence that intercellular communication through Hh signals can regulate the MT 
cytoskeleton and MT-dependent processes by affecting the level of tubulin acetylation. 
 
There has been a report showing that Hh signaling promotes α-tubulin acetylation (Lee and 
Ko, 2016). I also found similar results in fibroblasts. After treating them with SAG, a synthetic 
Hh activator (Chen et al. 2002), induced levels of acetylated tubulin (AcTub) in 
immunofluorescence (Fig. 1A, B) and in Western blotting experiments (Fig. 1C, D) were 
observed. This AcTub increase correlated with the induction of the Hh pathway target GLI1 
and the levels of the Dual-specificity Tyrosine (Y)-regulated kinase 1B (DYRK1B, a.k.a. as 
MIRK) (Mercer and Friedman 2006b) which I have previously shown to be upregulated by 
Hh signaling (Singh et al. 2017) (Fig. 1D). I could obtain similar results with MEFs (Fig. 1E), 
demonstrating that this effect was not restricted to NIH3T3 cells. To rule out a Hh-unrelated 
effect of the compound SAG, I investigated MEF cells stably expressing SHH ligand 
(MEF[SHH] cells) and found that pathway inhibition with the SMO inhibitor SANT (Chen et al. 
2002) concomitantly reduced the levels of AcTub and DYRK1B (Fig. 1F). Based on these 
experiments my hypothesis was that DYRK1B could be involved in mediating all or some 
of the effects of Hh on AcTub. To investigate further, endogenous Dyrk1b was knocked 
down by RNAi in MEF cells. The SAG-mediated increase in acetylated tubulin could be fully 
 Results 
 
26 
blocked upon removal of DYRK1B (Fig. 1G). Supporting my results further, the elevated 
AcTub levels in MEF[SHH] cells could be reduced by siRNA transfection targeting Dyrk1b 
(Fig. 1H). These experiments suggest that Hh signaling increases DYRK1B protein levels 
by posttranscriptional mechanisms leading to a rise in DYRK1B-mediated tubulin 
acetylation. 
 
To understand the role of DYRK1B in more detail I generated NIH3T3 cells stably 
expressing a V5-tagged form of this kinase (NIH3T3[1B] cells). Interestingly, there was a 
striking difference in the morphology when compared to control cells (Figure 2A). Control 
cells were elongated and had a spindle-shaped morphology of mesenchymal cells whereas 
the DYRK1B-overexpressing cells had much smaller and rounder cell bodies with longer 
cellular extensions, suggesting a potential cytoskeletal effect induced by the increased 
DYRK1B expression. AcTub levels were found to be strikingly elevated in these cells (Fig. 
2B, C, D), showing that the sole overexpression of DYRK1B can lead to AcTub induction. I 
could recapitulate these finding in HeLa cells stably expressing DYRK1B (Fig 2E, F, G). As 
HDAC6 is known as a major determinant of the tubulin acetylation status, I used the 
Hela[DYRK1B] cells to investigate whether DYRK1B expression affects HDAC6 enzyme 
activity when compared to control cells. I immunoprecipitated endogenous HDAC6 from 
control and from DYRK1B-expressing HeLa cell lines and subjected the precipitate to a 
luminometric in vitro deacetylase assay. Indeed, the HDAC6 enzyme activity (normalized 
to the amount of total HDAC6 protein precipitated) was significantly lower (by about 40 %) 
in DYRK1B-expressing cells. This difference was blunted when an HDAC6-selective 
inhibitor (Cay10603) was co-applied to the deacetylase assay (Fig. 2H). With these 
experiments, I could conclude that increased expression of DYRK1B is sufficient to elicit 
MT acetylation in the absence of additional Hh receptor activation. Furthermore, increased 
DYRK1B levels result in functional downregulation of HDAC6, a known master regulator of 
MT acetylation. 
 
I wanted to investigate the mechanism by which DYRK1B and HDAC6 are related. There 
have been reports suggesting a stimulatory effect of Glycogen synthase kinase 3 β (GSK3β) 
on HDAC6 (Chen et al. 2010). I worked further to determine if Hh/DYRK1B would inhibit 
GSK3β, thereby indirectly leading to the suppression of HDAC6 activity. To this end, I 
treated the cells with SAG and could clearly see the elevated phosphorylation of GSK3ß at 
Ser9 (Fig. 3A) and SANT treatment reduced levels of GSK3ß (Fig. 3B) phosphorylation. To 
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investigate how DYRK1B affects GSK3ß phosphorylation, I knocked down Dyrk1B in 
continuously SHH-expressing cells, and this led to a clear reduction in phospho-GSK3ß 
levels (Fig. 3C). Adding to this, pharmacological blockade of DYRK1B with the inhibitor 
DYRK1B (Ashford et al. 2014), also reduced the phospho-GSK3ß levels in SAG treated 
cells (Fig. 3D). Moreover, stable expression of DYRK1B was enough to elevate phospho-
GSK3ß levels (Fig. 3E), which suggests a close functional connection between the two 
players. Thereby, I performed in vitro kinase assays and could see that the recombinant 
DYRK1B was able to phosphorylate GSK3ß (Fig. 3F). My data suggest that Hh signaling, 
by upregulation of DYRK1B, phosphorylates GSK3ß (inactive) and hence inhibits HDAC6 
enzyme activity. 
 
It is already known that HDAC6 and GSK3β are localized to MTs (Hubbert et al. 2002; 
Kovacs et al. 2004; Sun et al. 2012). I wanted to find if DYRK1B is also localized to MTs. 
To this end I performed biochemical MT-association assay (MTaa), using control and SAG 
treated NIH3T3 fibroblasts, and looked at the protein fractions bound to polymerized 
microtubules. I could clearly see, a fraction of total DYRK1B and GSK3ß (positive control) 
at polymerized microtubule protein fractions (Fig. 4A). To support my observations further, 
I performed sub-diffraction super-resolution microscopy (GSD-Ground State Depletion 
microscopy) and were able to visualize transfected V5-tagged DYRK1B on endogenous 
MTs (Fig. 4B) in human fibroblasts (PSC). With the help of this type of microscopy, I could 
also visualize the localization of endogenous DYRK1B on single MT tracks in HeLa cells 
(Fig. 4C). As a positive control, I was able to detect endogenous HDAC6 on defined MT 
tracks in PSC fibroblasts (Fig. 4D). With these experiments, I could prove that DYRK1B is 
associated with MTs. 
 
After looking into the mechanical aspects of Hh-DYRK1B-GSK3β-HDAC6-AcTub axis, I 
looked at the functional consequences of this process. To this end, I analyzed MT-
dependent mitochondrial transport where tubulin acetylation had been shown to facilitate 
organelle motility in neurons (Chen et al. 2010). I wanted to find out if Hh signaling also 
affects the mitochondrial transport and to this end, I generated NIH3T3 cells stably 
expressing fluorescent Dendra protein fused to a mitochondrial targeting sequence derived 
from human cytochrome c oxidase subunit 8a (NIH[Cox8a-Dendra] cells). The 
mitochondrial expression of this fusion protein was verified by its perfect co-localization with 
MitoTracker (Fig. 5A). Also the SAG and DYRK1B dependent regulation of AcTub levels 
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were verified in these cells (Fig. 5B) Thereafter, I looked at the impact of Hh activation 
(SAG), DYRK1B inhibition (AZ191) and HDAC6 inhibition (ACY-1215 (Santo et al. 2012)) 
on mitochondrial transport by using live cell imaging. My results have clearly shown that 
overall track length of mitochondrial transport is considerably increased with SAG 
stimulation and HDAC6 inhibition, whereas this effect could be completely abrogated with 
DYRK1B inhibition by AZ191 (Fig. 5C). Adding to these results, the mitochondrial track 
speed was also increased with HDAC6 inhibition, and Hh activation (SAG) whereas 
DYRK1B inhibition by AZ191 completely abrogated this effect (Fig. 5D). Plotting the Mean 
square displacement (MSD), which is a measure of the deviation of the position of cells, 
with respect to a reference position over time, showed us increased directionality with SAG 
and reduced directionality with DYRK1B inhibition with AZ191. HDAC6 inhibition by ACY-
1215 also led to an increased directionality, which suggests that increased tubulin 
acetylation enhances the mitochondrial transport (Fig. 5E). With these results, I could prove 
that Hh signaling promotes MT based mitochondrial transport and that DYRK1B plays a 
critical role in this process.  
 
Another important MT-dependent functional process is the polarization of migrating 
mesenchymal cells. In this process, the microtubule organizing center (MTOC) is re-
oriented towards the wound (scratch made on the confluent NIH3T3 fibroblasts). I 
performed the in vitro wounding assays in confluent fibroblast cultures and stained for the 
MTOC (using an α-Pericentriolar material 1 (PCM-1) antibody) and the MT cytoskeleton 
(αTub antibody). A scratch was made in the confluent cultures on the glass coverslip, and 
positive polarization towards the wound is indicated by an asterisk. As can be seen in Fig. 
6A and 6B, induction of Hh signaling by SAG and inhibition of HDAC6 by ACY-1215 led to 
an increased polarization towards the wound. When I pharmacologically blocked DYRK1B 
by AZ191, I could see that it reduced the polarization process (Fig. 6C). To investigate 
further, I tested the impact of DYRK1B inhibition on Hh-driven scratch wound closure using 
live-cell imaging (Fig. 6D). In line with my previous results, SAG promoted the migration of 
NIH3T3 fibroblasts into an in vitro wound whereas DYRK1B inhibition reduced the migratory 
potential. This result was quantified and represented in Fig. 6E. This shows the importance 
of DYRK1B in Hh induced fibroblast polarization and cell motility. 
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6 Discussion 
 
6.1 DYRK1B regulates Hh signaling pathway 
 
Earlier reports on the role of DYRK1B on Hh pathway stated positive (Gruber et al. 2016) 
as well as negative (Lauth et al. 2010; Jacob et al. 2011; Keramati et al. 2014b) regulatory 
functions to this kinase. With my findings, I have bring together the previous results and 
clarify the regulatory role of DYRK1B in more detail. With my data, I have shown the dual 
and sometimes an opposing interaction of this kinase with Hh pathway: 1.) The ectopic 
expression of DYRK1B has been shown to block canonical SMO-initiated signaling, 
although the exact mechanism still needs to be elucidated. 2.) On the other hand, 
overexpressed DYRK1B stabilizes GLI1 by rescuing it from proteasomal degradation. 
DYRK1B is also known to activate the PI3K/mTOR/AKT signaling arm and there have been 
reports showing that AKT phosphorylates and protects GLI transcription factors from decay 
(Riobo et al. 2006; Shi et al. 2015). 3.) DYRK1B activates the PI3K/mTOR/AKT pathway 
which is subject to intense feedback regulation (Manning and Cantley 2007) and thereby 
the whole DYRK1B-Hh/GLI-system is subject to pronounced feedback control, which 
results in a strong kinetic influence on the Hh pathway output. As shown by my results, 
short-term inhibition of DYRK1B resulted in increased GLI protein levels whereas, long-term 
blockade of DYRK1B led to decreased GLI protein levels. With these findings, I would 
suggest, that the earlier reports, might have considered a specific part of the entire crosstalk 
spectrum and with these results, I could explain most, if not all the published results about 
the regulatory effects of DYRK1B on Hh signaling. The role of oncogenic RAS on Hh 
signaling has also been reported for its dubious effects (Ji et al. 2007; Stecca et al. 2007; 
Lauth et al. 2010; Zhao et al. 2015). And DYRK1B has been shown as a downstream 
effector of mutant KRAS (Jin et al. 2007) and was also discovered as synthetic lethal gene 
partner of mutant KRAS in a screen (Barbie et al. 2009), which might be explained by my 
results showing a connection between DYRK1B and PI3K/mTOR/AKT signaling. Adding to 
this the discovery of DYRK1B mutations in the metabolic syndrome and its involvement with 
PI3K signaling are fascinating.  
 
Interestingly, I could observe the stress-induced response of DYRK1B kinase in one specific 
cell line tested which was able to promote GLI1 stability, even in the absence of clearly 
measurable Gli1 and Gli2 mRNA expression (Fig. 1F, S1D). Considering this effect, I could 
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imagine that GLI1 would be activated in various pathological events, by unrelated Hh 
regulators which, induce DYRK1B expression, bypassing the need for increased GLI1/2 
mRNA levels. My results have shown that ectopic expression of DYRK1B altered the 
appearance of GLI1 protein isoforms and a new 100 kDa variant was generated. Although, 
previous findings have also mentioned a variant of this size to be inhibitory (Stecca and 
Ruiz i Altaba 2009), another shorter isoform of 130 kDa seems to be activating (Amable et 
al. 2014). My data leads us to some of the open questions, about the shorter GLI1 isoform 
and would require further investigations.  
 
There is enough evidence that Hh signaling leads to the induction of various kinases, 
including protein kinase B (PKB) or AKT. AKT kinase is a key mediator of PI3K signaling 
pathway and has two phosphorylation sites at Ser473 and Th308. My results have shown 
that DYRK1B is upregulated by SAG, and overexpression of this kinase leads to induced 
levels of mTOR and AKT phosphorylation, and depletion of this kinase by RNAi, abrogates 
the ability of Hh signaling to induce phosphorylation. The PI3K/mTOR/AKT pathway is one 
of the most frequently activated signaling cascades in human cancer (Fruman and Rommel 
2014). The mTOR kinase is composed of two multi-protein complexes, mTORC1 and 
mTORC2. The first complex is downstream of AKT and is activated through TSC1/2 and 
Rheb proteins whereas the latter complex is upstream of AKT and is activated by PI3K in 
an unknown manner (Shimobayashi and Hall 2014). The mTORC1 complex is known for 
being a major regulator of protein translation and autophagy while mTORC2, amongst 
others, impinges on cell survival through regulation of FOXO and PKCα (Guertin et al. 2006; 
Shiota et al. 2006). My hypothesis that DYRK1B might regulate mTORC2, as both of them 
is shown to phosphorylate AKT at Ser473. Also, confirming the results of RNAi, I could show 
that with the knockdown of the DYRK1B kinase, phosphorylation levels of AKT at Ser473 
are reduced, but it had no effect phospho-S6/S6K (read-out of mTORC1 activity). As AKT, 
DYRK1B has also been described as a survival kinase before (Deng et al. 2006; Mercer et 
al. 2006).  
 
Altogether, my results describe a complex crosstalk between DYRK1B and Hh signaling. 
As per the suggested model, the effects of DYRK1B kinase on oncogenic Hh signaling are 
dependent on several factors, such as the expression level of DYRK1B, canonical/non-
canonical Hh signaling, analysis time intervals or cell type. Due to these varying factors, 
which can affect the plausible outcome, if DYRK1B kinase is used in a clinical setting as a 
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target, I tried a combination treatment where I used pharmacological inhibitors of DYRK1B 
along with inhibitors of AKT, mTOR, and S6K. In DYRK1B amplified pancreatic and ovarian 
cancer cells the combination treatment yielded increased cell death and a significant 
reduction in GLI1 level which could direct us to have novel cancer therapy in the future. 
 
6.2 DYRK1B regulates Hh induced tubulin acetylation 
 
Microtubule-dependent cellular processes have been widely studied and the mechanism 
behind these processes is very well known. But, how different signaling pathways and 
extracellular ligands affect the cytoskeletal events, is largely unknown. With my results, I try 
to show how Hh signaling affects MT acetylation and MT-dependent processes by DYRK1B 
induction. DYRKs, unlike many other kinases, are mainly regulated by their overall 
abundance, thereby a slight increase in the amount could have large and significant effects 
on various cellular processes. This is shown for instance by the devastating effect of the 
1.5-fold increase in DYRK1A on neuronal and brain development in Down syndrome 
(Trisomy 21) patients (Gardiner et al. 2010; Duchon and Herault 2016). DYRK1B kinase 
has been known to promote motility in ovarian cancer cells (Collins et al. 2006) which often 
harbor a 19q13 chromosomal DYRK1B-containing amplicon or display elevated levels of 
DYRK1B kinase expression by other means (Friedman 2013). In addition, work in 
pancreatic cancer has shown DYRK1B can protect the cells from the depolymerization 
agent Nocodazole (Deng et al. 2006). My findings, provide a mechanistic explanation for 
these observations and show that DYRK1B regulates MT acetylation. I have shown that the 
cellular DYRK1B pool is localized to microtubule cytoskeleton. Ectopic expression of 
DYRK1B promotes the phosphorylation of GSK3β at Ser9 position, which in turn inactivates 
GSK3β. GSK3β has been shown to have a stimulatory effect on HDAC6. Thereby, 
overexpression of DYRK1B kinase leads to inactivation of GSK3β which in turn leads to the 
reduction of HDAC6 activity, which regulates tubulin acetylation. GSK3β and HDAC6 are 
known to associate with MTs and as shown in Fig. 6F, I can speculate that these proteins 
form a functional unit around microtubules. The elucidation of how exactly HDAC6 is 
regulated by GSK3β awaits further studies. 
 
DYRK1B is known to modulate the PI3K/mTOR/AKT signaling pathway, where feedback 
control mechanisms play a critical role (Singh et al. 2017). Glycogen synthase kinase 3 
(GSK-3) has been shown to affect several biological processes such as metabolism gene 
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expression, cell fate determination, proliferation, and survival. GSK-3 activity is inhibited 
through phosphorylation of serine 21 in GSK-3 alpha and serine 9 in GSK3β. AKT is known 
to phosphorylate GSK3β, independent of the DYRK1B kinase. Due to this complex 
crosstalk, the final effect on tubulin acetylation is difficult to speculate, especially when 
feedback mechanisms are active.  
 
My results support Hh mediated tubulin acetylation and this is in line with the previously 
published data (Lee and Ko 2016). With my findings, I address more mechanistic approach 
by integrating extracellular Hh ligands to intracellular cytoskeletal outputs. In this respect, it 
is interesting to note that both, Hh signaling as well as HDAC6 inhibition/MT acetylation 
were found to drive Interleukin-10 production, which is an anti-inflammatory cytokine and 
has multiple pleiotropic effects (Wang et al. 2014; Lee et al. 2016a). From previous reports, 
and my results, which are in line with the findings, I know that DYRK1B and HDAC6 are the 
regulatory components of the Hh cascade which, increases the possibility for cytoskeleton-
mediated autoregulation of the pathway (Lauth et al. 2010; Dhanyamraju et al. 2014; Gruber 
et al. 2016). Hedgehog signaling pathway is often subject to a complex crosstalk, and my 
results, show that the effects on MT regulation are dependent on tubulin-PTMs, and not 
through motor proteins. Thereby understanding the regulation of cell migration became 
more complicated. Whether these processes involve canonical or non-canonical pathway 
activation, needs further work. Several noncanonical mechanisms have been reported to 
modulate Hh induced cell migration such as non-ciliary SMO and/or Gli-independent 
regulation of the actin cytoskeleton (Bijlsma et al. 2007; Polizio et al. 2011a; Polizio et al. 
2011b; Bijlsma et al. 2012). 
 
With my results, I have looked at the functional aspects of the microtubule regulation by 
post-translational modifications and have shown that Hh signaling promotes mitochondrial 
transport along microtubules in fibroblasts. These were considerably novel work as, before 
this, studies have reported MT-based mitochondrial motility in neuronal cells where long 
axons mediate the mitochondrial transport to distant sites for local ATP production (Saxton 
and Hollenbeck 2012). There have been studies showing the importance subcellular 
localization of mitochondria in migrating epithelial cancer cells (Desai et al. 2013). As per 
the central bioenergetics role of mitochondria in eukaryotic cells, several links have been 
suggested on metabolic regulation of mitochondrial dynamics (Mishra and Chan 2016). At 
the same time, studies have shown DYRK1B mutations in families with metabolic syndrome 
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(Keramati et al. 2014a) where a potential role of mitochondria would be interesting to follow 
up.  
Altogether, with my results I have shown how ligand based Hh signaling pathway modulates 
the PTM of MTs and positively affect DYRK1B kinase and subsequently affect the 
intracellular processes like cell polarization, migration and organelle transport.  
 
6.3 Emerging Roles of DYRKs in Embryogenesis & Hh Pathway Control 
 
DYRK family of kinases have been highly conserved from yeast to humans. In my review, I 
have tried to outline the currently available knowledge on the DYRK family of kinases 
engaging in developmental biology, physiology, and pathology, focusing on its impact on 
Hh signaling. I have also discussed the significance of this family of kinases and their roles 
in embryogenesis and Hh signaling pathway. Several reports have linked DYRK kinases to 
Hh signaling, which suggests a close regulation between these kinases and Hh signaling. 
Henceforth, it can be hypothesized that they contribute to Hh mediated steps during 
embryonic development. Although a clear mechanistic picture is still missing, which would 
identify the intense crosstalk between DYRKs and Hh, particularly in in vivo settings. As 
certain DYRKs have a preferred expression in specific tissues (e.g., DYRK1A in neuronal 
and DYRK1B in muscle tissue), it is reasonable to speculate that the impact on the tissue-
selective Hh pathway activity is specified by the respective DYRK enzyme. Although, some 
sort of functional redundancy might exist, in tissues or cell types where several DYRK 
kinases are expressed together. DYRK1A has been linked intensively with neuronal tissue 
development and it has prosurvival function and negatively regulates the apoptotic process. 
DYRK1B has been linked with muscle tissue and enhances the transcriptional activity of 
TCF/HNF1A and FOXO1. It has been also shown to promote adipogenesis. From a 
therapeutic point of view, this might be important for the development of small molecule 
inhibitors, which might lack necessary specificity and target several DYRKs simultaneously. 
DYRK kinase has also been known to modulate other signaling pathways, such as the 
NFAT (nuclear factor of activated T-cells) (Gwack et al. 2006) pathway or HIF (hypoxia-
inducible factor) signaling (Lee et al. 2016c). Future work will reveal whether Hedgehog or 
any of the other signaling systems is particularly important for the physiological impact of 
DYRK kinases. 
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Most studies for developmental crosstalk between DYRKs and Hh stems from DYRK1A, 
neuronal development, and Down syndrome. Although in recent studies on DYRK1B and 
DYRK2 discussing the roles of Hh signaling in muscle development, adipocytic 
differentiation has also helped in understanding other family members of DYRKs. Recent 
reports involving the effects of DYRKs in metabolic syndrome and cancer have given us the 
cue for interesting and significant roles of these kinases in cross-talk with Hh and other 
signaling pathways.  
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Abstract 41 
The posttranslational modification (PTM) of tubulin subunits is important for the 42 
physiological functions of the microtubule (MT) cytoskeleton. Although major advances have 43 
been made in the identification of enzymes carrying out MT-PTMs, little knowledge is 44 
available on how intercellular signaling molecules and their associated pathways regulate 45 
MT-PTM-dependent processes inside signal-receiving cells. Here we show that Hedgehog 46 
(Hh) signaling, a paradigmatic intercellular signaling system, affects the MT acetylation state 47 
in mammalian cells. Mechanistically, Hh pathway activity increases the levels of the MT-48 
associated DYRK1B kinase, resulting in the inhibition of GSK3β through phosphorylation of 49 
Serine 9 and the subsequent suppression of HDAC6 enzyme activity. Since HDAC6 represents 50 
a major tubulin deacetylase, its inhibition increases the levels of acetylated MTs. Through 51 
the activation of DYRK1B, Hh signaling facilitates MT-dependent processes such as 52 
intracellular mitochondrial transport, mesenchymal cell polarization or directed cell 53 
migration. Taken together, we provide evidence that intercellular communication through 54 
Hh signals can regulate the MT cytoskeleton and contribute to MT-dependent processes by 55 
affecting the level of tubulin acetylation.  56 
57 
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Introduction 58 
The microtubule (MT) cytoskeleton is crucial for a vast number of cellular processes 59 
including signal transduction, organelle transport, mitosis and cell migration. A major mode 60 
of MT regulation is through posttranslational modification (PTM) such as acetylation, 61 
phosphorylation, polyglycylation, polyglutamylation and others [1-3]. One of the best-62 
studied modification is acetylation, which can occur on Lys40 of the α-subunit of the α/β-63 
heterodimer within MTs. Acetylated α-tubulin (AcTub) is often associated with stable and 64 
long-lived MTs, such as those observed e.g. in primary cilia. Although initial speculations 65 
about tubulin PTMs affecting transport velocity along MTs were questioned later, these 66 
modifications seem to determine the binding specificity of selected motor proteins and 67 
thereby facilitate the transport of certain cargoes along MT tracks [4-7]. Indeed, increasing 68 
tubulin acetylation has been shown to promote MT-directed mitochondrial transport in 69 
neurons [8] and to compensate for vesicular transport deficits in a cellular model of 70 
Huntington’s disease [9]. Moreover, recent data show that acetylation protects MTs from 71 
mechanical breakage, which might affect transport processes indirectly [10, 11].  72 
Key enzymes regulating MT acetylation are α-tubulin acetyl transferase (ATAT, a.k.a. αTAT1 73 
or MEC17) and histone deacetylase 6 (HDAC6), which add or remove acetyl groups from α-74 
tubulin, respectively [12-14]. HDAC6 is a multifunctional protein with sequence homology to 75 
nuclear HDACs, deacetylating many non-histone proteins such as tubulin [15]. It is involved 76 
in a wide variety of cellular processes including signal transduction [16-19], aggresome 77 
formation [20, 21], stress granule biology [22] and gene transcription [23].  78 
Although a lot of information about the enzymes governing tubulin PTMs has been gathered 79 
in recent years, comparatively little knowledge is available about how this cytoskeletal 80 
regulation is controlled by signaling networks. This information would be of particular 81 
interest as signaling pathways are perfectly suited to sense extracellular conditions and to 82 
translate these cues into modifications of the intracellular cytoskeleton. 83 
One example of such a signaling system is the evolutionary conserved Hedgehog (Hh) 84 
pathway. Hedgehog signaling is absolutely essential for proper embryonic development [24, 85 
25] and its overactivation is associated with numerous forms of cancer [26-28]. In many 86 
instances during development, tissue repair or cancer, Hh ligands (Sonic Hh (SHH), Desert Hh 87 
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(DHH), Indian Hh (IHH)) signal from epithelial to neighboring mesenchymal cell types [29, 88 
30]. Binding to the primary cilia-localized Patched1 (PTCH1) receptor releases Smoothened 89 
(SMO) from PTCH1-mediated inhibition and allows for the activation of the GLI family of 90 
transcription factors (GLI1, GLI2, GLI3) [31-35].  While Hh signaling has been shown to affect 91 
the actin cytoskeleton [36-39], very little is known about its effects on MTs. 92 
In this work, we show that activated Hh signaling promotes the acetylation of microtubules 93 
and contributes to AcTub-dependent processes such as cell polarization, migration or 94 
organelle transport. Mechanistically, we identify the Hh-regulated DYRK1B kinase as a 95 
negative modulator of GSK3β, leading to the suppression of HDAC6 enzyme activity and an 96 
increase in tubulin acetylation. Using biochemical assays as well as super-resolution 97 
microscopy we could further show that DYRK1B, GSK3β and HDAC6 are associated to MTs. In 98 
summary, using Hh signaling as a paradigm, we describe a mechanistic framework how 99 
intercellular communication can impinge on cytoskeletal regulation and cell function.   100 
101 
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Results 102 
Hedgehog signaling regulates tubulin acetylation 103 
In line with another recent report [40], we found that Hh signaling promotes the increase of 104 
α-tubulin acetylation in fibroblasts, a cell type representing a major Hh-responsive cell 105 
population in vivo. When NIH3T3 cells, cultured under low serum conditions, were treated 106 
with the Hh pathway-activating synthetic compound SAG (Smoothened agonist) [41], we 107 
observed an induction of acetylated tubulin (AcTub) in immunofluorescence (Fig. 1A,B) and 108 
in Western blotting experiments (Fig. 1C,D). This AcTub increase correlated with the 109 
induction of the Hh pathway target GLI1 and the levels of the Dual-specificity Tyrosine (Y)-110 
regulated kinase 1B (DYRK1B, a.k.a. as MIRK) [42] which we have previously shown to be 111 
upregulated by Hh signaling  [43] (Fig. 1D). However, Dyrk1b mRNA levels were not 112 
significantly affected by Hh signaling, as were the levels of AcTub regulating enzymes such as 113 
Hdac6 and Mec17 (αTat1) (Fig. S1A), arguing for a post-transcriptional regulation of DYRK1B 114 
by Hh. 115 
Furthermore, Hh-induced tubulin acetylation and DYRK1B induction was also observed in 116 
other fibroblast cells such as in SAG-treated mouse embryonic fibroblasts (MEFs) (Fig. 1E), 117 
demonstrating that this effect was not restricted to NIH3T3 cells. To rule out a Hh-unrelated 118 
effect of the compound SAG, we investigated MEF cells stably expressing SHH ligand 119 
(MEF[SHH] cells) and found that pathway inhibition with the SMO inhibitor SANT [41] 120 
concomitantly reduced the levels of AcTub and DYRK1B (Fig. 1F). Based on these 121 
experiments we hypothesized that DYRK1B could be involved in mediating all or some of the 122 
effects of Hh on AcTub. 123 
In order to demonstrate that the Hh-induced AcTub increase was indeed mediated through 124 
DYRK1B, we knocked down endogenous Dyrk1b by means of RNAi in MEF cells. As can be 125 
seen in figure 1G, the SAG-mediated increase in acetylated tubulin could be fully blocked 126 
upon removal of DYRK1B. In support of our finding of Hh-regulated tubulin acetylation, the 127 
elevated AcTub levels previously seen in MEF[SHH] cells could be reduced by siRNA 128 
transfection targeting Dyrk1b (Fig. 1H). These experiments suggest that Hh signaling 129 
increases DYRK1B protein levels by posttranscriptional mechanisms leading to a rise in 130 
DYRK1B-mediated tubulin acetylation.  131 
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 133 
The expression of DYRK1B is sufficient for AcTub induction 134 
Given the cross-talk between Hh signaling and tubulin acetylation, we were interested to 135 
address the role of DYRK1B in more detail. To this end, we generated NIH3T3 cells stably 136 
expressing a V5-tagged form of this kinase (NIH3T3[DYRK1B] cells). Intriguingly, these cells 137 
displayed a strikingly different morphology in culture when compared to control cells (Figure 138 
2A). While control cells (NIH3T3[Mock]) possessed the expected elongated, spindle-shaped 139 
morphology of mesenchymal cells, the DYRK1B-overexpressing cells had much smaller and 140 
rounder cell bodies with longer cellular extensions, suggesting a potential cytoskeletal effect 141 
induced by the increased DYRK1B expression. Indeed, when analyzing the levels of AcTub in 142 
these cells, we found strikingly elevated levels of acetylated tubulin (Fig. 2B,C,D), showing 143 
that the sole overexpression of DYRK1B can lead to AcTub induction. Intriguingly, DYRK1B-144 
induced acetylated MT were more resistant to the depolymerizing activity of Nocodazole 145 
(Fig. S2A,B), which is in line with a previous report describing a protective function of 146 
DYRK1B against Nocodazole [44]. We furthermore investigated whether an increased 147 
DYRK1B expression might affect the morphology of primary cilia, a cellular organelle rich in 148 
AcTub and essential for proper Hh signal transduction [45, 46]. However, by using 149 
immunofluorescent staining with an α-detyrosinated tubulin antibody (a primary cilia 150 
marker) as well as by electron microscopy we were unable to detect obvious morphological 151 
aberrations in the (ultra)structure of primary cilia upon DYRK1B overexpression (Fig. S2C). 152 
Next, we went on to investigate whether the finding of increased AcTub levels in DYRK1B-153 
expressing cells was specific to fibroblasts. As can be seen in figures 2E,F,G, we could 154 
recapitulate these observation also in Hela cells stably transfected with DYRK1B (Hela[DYRK1B] 155 
cells). Since HDAC6 is known as a major determinant of the tubulin acetylation status, we 156 
used the Hela[DYRK1B] cells to investigate whether DYRK1B expression would diminish the 157 
overall HDAC6 enzyme activity when compared to control cells. We immunoprecipitated 158 
endogenous HDAC6 from control and from DYRK1B-expressing Hela cell lines and subjected 159 
the precipitate to a luminometric in vitro deacetylase assay. Indeed, the HDAC6 enzyme 160 
activity (normalized to the amount of total HDAC6 protein precipitated) was significantly 161 
lower (by about 40 %) in DYRK1B-expressing cells. This difference was blunted when a 162 
HDAC6-selective inhibitor (Cay10603) was co-applied to the deacetylase assay (Fig. 2H). 163 
Taken together, these experiments demonstrate that the increased expression of DYRK1B is 164 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
sufficient to elicit MT acetylation in the absence of Hh receptor activation. Furthermore, 165 
increased DYRK1B levels result in functional downregulation of HDAC6, a known master 166 
regulator of MT acetylation. 167 
 168 
 169 
DYRK1B phosphorylates the inhibitory Ser9 site of GSK3β  170 
In our attempts to decipher the mechanistic link between DYRK1B and HDAC6, we 171 
speculated that the DYRK1B kinase might directly phosphorylate HDAC6. To address this 172 
issue, we performed in vitro kinase assays with both proteins but failed to observe a direct 173 
phosphorylation (not shown), which prompted us to hypothesize an indirect mechanism. 174 
One example of such a mechanism would envision that DYRK1B does not phosphorylate 175 
HDAC6 directly, but instead phosphorylates an HDAC6-regulating protein. Therefore, we 176 
focused on Glycogen synthase kinase 3 β (GSK3β), which had previously been shown to 177 
regulate HDAC6 in a stimulatory manner [8]. Hence, we wanted to find out whether 178 
Hh/DYRK1B would inhibit GSK3β, thereby indirectly leading to the suppression of HDAC6 179 
activity. To this end, we first investigated whether Hh signaling modulates GSK3β. In fact, 180 
immunoblot analyses of lysates from SAG-treated cells revealed that Hh activity promotes 181 
the phosphorylation of Ser9 (Fig. 3A), an important regulatory residue known to control 182 
phosphorylation-induced GSK3β inactivation. In contrast, blocking Hh pathway activity in 183 
continuously SHH-expressing cells reduced the levels of phospho-GSK3βS9 (Fig. 3B).  184 
Next, we investigated whether DYRK1B plays a role in Hh-induced GSK3β phosphorylation 185 
and found that RNAi-mediated knock-down of endogenous Dyrk1b resulted in a concomitant 186 
reduction of phospho-GSK3βS9 levels in MEF[SHH] cells (Fig. 3C). In addition, the 187 
pharmacological blockade of DYRK1B with the selective inhibitor AZ191 [47] reduced 188 
phospho-GSK3βS9 and AcTub levels in SAG-treated cells (Fig. 3D). Moreover, the stable 189 
expression of DYRK1B (in the absence of Hh signaling) was sufficient to induce GSK3β 190 
phosphorylation (Fig. 3E), suggesting a close functional connection between these two 191 
players. Therefore, we performed in vitro kinase assays and found that recombinant DYRK1B 192 
was able to phosphorylate immunoprecipitated GSK3β on Ser9 under in vitro conditions 193 
(Fig. 3F). In summary, we could provide evidence that Hh signaling, through upregulation of 194 
DYRK1B, inactivates GSK3β by phosphorylation on the important control residue Ser9. This 195 
subsequently inhibits HDAC6 enzyme activity, leading to an increase in cellular AcTub levels.     196 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
 197 
 198 
DYRK1B is associated with the MT cytoskeleton 199 
Since our data suggested that DYRK1B regulates tubulin acetylation and since it was known 200 
that HDAC6 and GSK3β are localized to MTs [12, 48-50], we were interested whether 201 
DYRK1B would also be associated to MTs. To analyze this issue in more depth, we performed 202 
biochemical MT-association assays (MTaa) using control or SAG-treated NIH3T3 cells in order 203 
to purify protein fractions bound to polymerized MTs. As can be seen in figure 4A, a fraction 204 
of total DYRK1B (as well as GSK3β which was included as positive control) could consistently 205 
be found in the pelleted fraction (‘MT’) containing polymerized MTs. Stimulation with the 206 
SMO agonist SAG led to increased levels of MT-bound DYRK1B, which was however most 207 
likely due to an overall increase in protein amount and not due to a specific recruitment to 208 
MTs.  209 
In order to support the MT-localization of DYRK1B by an independent technical approach, 210 
we performed sub-diffraction super-resolution microscopy (GSD-Ground State Depletion 211 
microscopy) and were able to visualize transfected V5-tagged DYRK1B on endogenous MTs 212 
(Fig. 4B) in human fibroblasts (PSC). As shown in figure S3A, DYRK1B also regulates AcTub 213 
levels in these cells. In addition, super-resolution microscopy also revealed the localization of 214 
endogenous DYRK1B on single MT tracks in Hela cells (which were used as the endogenous 215 
DYRK1B levels in PSC cells were difficult to visualize by microscopy) (Fig. 4C). As a positive 216 
control of another protein previously reported to be MT-associated, we were able to detect 217 
endogenous HDAC6 on defined MT tracks in PSC fibroblasts (Fig. 4D). Taken together, using 218 
biochemical as well as microscopic techniques we could provide evidence for DYRK1B being 219 
associated with MTs, the expected subcellular localization for a MT-regulating protein.  220 
 221 
 222 
Hh signaling enhances the intracellular transport of mitochondria  223 
After having investigated mechanistic aspects of the Hh-DYRK1B-GSK3β-HDAC6-AcTub axis, 224 
we wanted to address the functional consequences of this chain of events. To this end, we 225 
investigated different cellular processes which have been described as being dependent on 226 
MTs and which are potentially influenced by MT-PTMs: Intracellular mitochondrial transport 227 
and mesenchymal cell polarization coupled with directed cell migration. First, we analyzed 228 
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MT-dependent mitochondrial transport where tubulin acetylation had been shown to 229 
facilitate organelle motility in neurons [8]. In order to investigate whether Hh signaling 230 
affects mitochondrial transport, we generated NIH3T3 cells stably expressing fluorescent 231 
Dendra protein fused to a mitochondrial targeting sequence derived from human 232 
cytochrome c oxidase subunit 8a (NIH[Cox8a-Dendra] cells). The mitochondrial expression of this 233 
fusion protein was verified by its perfect co-localization with MitoTracker (Fig. 5A). In 234 
addition, we also verified the SAG- and DYRK1B-dependent regulation of AcTub levels in 235 
these cells (Fig. 5B).  236 
Using live cell imaging on the NIH[Cox8a-Dendra] cells, we first demonstrated that MT 237 
depolymerization by means of Nocodazole addition significantly reduced the overall distance 238 
(track length) and the speed of labelled mitochondria, verifying the importance of MT-239 
dependent transport in this process (Fig. S4A,B). In addition, when we plotted the mean 240 
square displacement (MSD) rate as a quantitative measure for directionality [51], we 241 
observed a decreased directionality in mitochondrial transport, as would be expected in a 242 
situation in which the MT tracks have been destroyed (Fig. S4C). 243 
Next, we investigated the impact of Hh activation (SAG), DYRK1B inhibition (AZ191) and 244 
HDAC6 inhibition (ACY-1215 [52]) on mitochondrial transport. We decided to measure a 245 
longer time frame (3h) than in the previous Nocodazole experiment, with less resolution in 246 
order to get an idea of physiologically meaningful intracellular distances (although this 247 
meant that we might not have recorded all short lateral movements). Nevertheless, our 248 
recordings clearly showed that, when compared to untreated control cells, SAG stimulation 249 
significantly increased the overall track length of transported mitochondria (Fig. 5C). 250 
Importantly, this effect could be completely abrogated by co-application of the DYRK1B 251 
antagonist AZ191 (Fig. 5C). In line with the hypothesized function of acetylated tubulin in 252 
organelle mobility, the mere induction of AcTub levels by the small molecule HDAC6 253 
inhibitor ACY-1215 also led to a significant increase in mitochondrial track length. In 254 
addition, also the mitochondrial transport speed was significantly increased by ACY-1215 255 
and there was a trend towards increased speed with SAG application. Again, 256 
pharmacological blockade of DYRK1B resulted in a clear reduction in mitochondria transport 257 
speed in SAG-treated cells (Fig. 5D). Plotting the MSD revealed that Hh signaling (SAG) 258 
increased the directed movement whereas the co-application of AZ191 completely 259 
abrogated this surplus in directionality (Fig. 5E). Moreover, inducing tubulin acetylation by 260 
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pharmacological HDAC6 inhibition (ACY-1215) also led to more directionality in 261 
mitochondrial transport, strongly suggesting that these effects are largely mediated through 262 
tubulin acetylation. In summary, we could provide evidence for Hh signaling enhancing MT-263 
based intracellular organelle transport and for a critical role of DYRK1B in this process. 264 
 265 
 266 
Hh promotes cell polarization and directed migration through DYRK1B 267 
In our attempts to link Hh signaling, DYRK1B and MT-PTMs to physiological events, we next 268 
turned to another MT-dependent process: The polarization of migrating mesenchymal cells, 269 
a process which can be recapitulated in in vitro wounding assays. In confluent cultures of 270 
fibroblasts, cells are usually not polarized towards a particular direction and the microtubule 271 
organizing center (MTOC) can be found randomly localized around the nucleus. However, if a 272 
scratch would is applied to the cultured monolayer, cells at the border re-orient their MTOC 273 
towards the wound. This sequence of events requires, among others, inactive GSK3β and the 274 
MT-bound motor protein dynein [53-56]. In addition, cell polarization and the subsequent 275 
directed cell migration towards the wound need the stabilization of MTs [54].  276 
Therefore, we performed in vitro wounding assays in confluent fibroblast cultures and 277 
stained for the MTOC (using an α-Pericentriolar material 1 (PCM-1) antibody) and the MT 278 
cytoskeleton (α-αTub antibody). As can be seen in figure 6A,B (and S5A), induction of Hh 279 
signaling by SAG led to an increase in cell polarization towards the wound. Increased cell 280 
polarization was also observed with the independent MT stabilizer ACY-1215 (HDAC6 281 
inhibitor) (Fig. 6A,B). In line with our previous results on the involvement of DYRK1B in 282 
AcTub regulation, we found that blocking DYRK1B function with AZ191 abrogated the Hh-283 
mediated mesenchymal cell polarization (Fig. 6C). 284 
As the polarization of mesenchymal cells is the first step for directed migration into e.g. 285 
wounded areas, we tested the impact of DYRK1B inhibition on Hh-driven scratch wound 286 
closure using live-cell imaging (Fig. 6D). As expected, when compared to control cells, SAG 287 
promoted the migration of NIH3T3 fibroblasts into an in vitro wound (Fig. 6E). When AZ191 288 
was co-administered, this increase in migratory potential was blunted, demonstrating an 289 
important role for DYRK1B in Hh-induced fibroblast polarization, cell motility and 290 
experimental wound closure. 291 
 292 
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 293 
Discussion 294 
A considerable amount of data has been accumulated on the mechanisms of MT-dependent 295 
cellular processes such as intracellular transport and mitosis, but little knowledge exists on 296 
how extracellular ligands actually modulate cytoskeletal events. Here, we show that Hh 297 
signaling has the capability to affect MT acetylation and MT-dependent processes through 298 
induction of DYRK1B. In contrast to many other kinases, DYRKs are mainly regulated through 299 
their overall abundance. Even small changes in total DYRK amount can have significant 300 
impact on cellular functions, as evidenced for instance by the devastating effect of the 1.5-301 
fold increase in DYRK1A levels on neuronal and brain development in Down syndrome 302 
(Trisomy 21) patients [57]. As such, we anticipate that also moderate Hh-induced DYRK1B 303 
increases could have larger effects on cellular processes, such as tubulin acetylation. We are 304 
however also aware of the fact that highly complex processes such as cell migration involve 305 
numerous regulators on several cellular levels and that the post-translational modification of 306 
tubulin most likely exerts a modifying role and is not the sole cause of these processes. 307 
DYRK1B has previously been identified as a potent pro-migratory gene in ovarian cancer cells 308 
[58], which often harbor a 19q13 chromosomal DYRK1B-containing amplicon or display 309 
elevated expression of this kinase by other means [59]. In addition, work in pancreatic 310 
cancer revealed that DYRK1B can protect cells from the MT-depolymerizing agent 311 
Nocodazole [44]. Our data provide a mechanistic explanation for these observations and 312 
present evidence for the role of this kinase in regulating MT acetylation. We find that a 313 
fraction of the cellular DYRK1B pool is localized to the microtubule cytoskeleton. 314 
Functionally, it inactivates GSK3β by direct phosphorylation of Ser9, leading to the indirect 315 
suppression of HDAC6 enzyme activity, a major cellular regulator of tubulin acetylation. 316 
Since both, GSK3β and HDAC6 can also associate to MTs, it is reasonable to speculate that 317 
these proteins form a functional unit at or around MTs (Fig. 6F). The elucidation of how 318 
exactly HDAC6 is regulated by GSK3β awaits further studies. 319 
 320 
Of note, we have previously shown that DYRK1B is able to manipulate PI3K/AKT signaling, 321 
which itself is subject to intense feedback control mechanisms [43]. As AKT can potentially 322 
phosphorylate GSK3β independently of DYRK1B, this complex network of signaling 323 
molecules could complicate the predictability of the net effect of tubulin acetylation, 324 
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particularly at time points at which feedback mechanism are still at play. Adding to this 325 
situation are somatic mutations activating the PI3K/AKT kinase arm in a constitutive manner 326 
as found in many cancer cells.  327 
Supporting and extending previously published evidence on Hh-regulated tubulin regulation 328 
[40], our manuscript integrates this regulation into a wider mechanistic framework ranging 329 
from Hh ligands to modulation of intracellular cytoskeletal outputs. In this respect, it is 330 
interesting to note that both, Hh signaling as well as HDAC6 inhibition/MT acetylation were 331 
found to drive Interleukin-10 production [60, 61]. Furthermore, DYRK1B and HDAC6 seem to 332 
be regulatory components of the Hh cascade itself, raising the possibility for cytoskeleton-333 
mediated autoregulation of the pathway [16, 62, 63]. 334 
Our results of Hh-mediated MT control through effects on tubulin-PTMs, and not through 335 
effects on e.g. motor proteins, add a new layer of complexity to the regulation of directed 336 
cell migration, a process involving a large number of proteins. Whether these effects utilize 337 
the canonical Hh signaling cascade or whether other ‘non-canonical’ mechanisms are 338 
responsible requires further investigations. Certain non-canonical mechanisms at several 339 
levels have been reported to modulate Hh-induced cell migration, such as non-ciliary SMO 340 
and/or GLI-independent regulation of the actin cytoskeleton [36-38, 64].  341 
Another interesting finding of this study is the fact that Hh signaling promotes the transport 342 
of mitochondria along MTs in non-neuronal cells such as fibroblasts. Until now, MT-based 343 
mitochondrial motility has been mostly investigated in neuronal cells, where long axons 344 
necessitate the transport of mitochondria to distant sites for local ATP production [65]. 345 
However, there is emerging evidence that the subcellular localization of mitochondria is also 346 
important for cell migration in non-neuronal cells [66]. In addition, the first links between 347 
mitochondrial dynamics and cellular metabolism are considered [67]. In light of the fact that 348 
DYRK1B has recently been associated with the metabolic syndrome [68, 69], a potential role 349 
of mitochondria will be interesting to follow up. Furthermore, Hh signaling has been 350 
implicated in controlling the functionality of the T-cell immunological synapse, a structure 351 
relying, among others, on motor-protein driven mitochondrial transport [70, 71]. 352 
In summary, we present a mechanistic framework how extracellular Hh ligands can 353 
modulate the PTM status of MTs and can subsequently contribute to the regulation of 354 
intracellular MT-dependent processes such as cell polarization, migration and organelle 355 
transport. 356 
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 357 
 358 
Material and Methods 359 
Cell lines 360 
NIH3T3 and HeLa cell lines were purchased from ATCC. MEF and MEF[SHH] cells were kindly 361 
provided by Wade Bushman [72]. PSC cells were a kind gift of M. Löhr [73]. The generation 362 
of NIH3T3 cells stably expressing empty vector control or DYRK1B was described in [43]. All 363 
cell lines were mycoplasma-free and were cultured in Dulbecco’s Modified Eagle Medium 364 
(DMEM (high Glucose plus Glutamine and Pyruvate), Invitrogen) supplemented with 10 % 365 
fetal bovine serum (FBS) and 1 % Penicillin/Streptomycin at 37°C with 5 % CO2. If not 366 
otherwise stated, serum concentrations were reduced to 0.5% during experiments for all cell 367 
types. 368 
 369 
Small-interfering RNA (siRNA) transfection 370 
Cells were transfected with 35 nM siRNA (Dharmacon SMARTpools and Qiagen control siRNA 371 
using RNAiMax (Invitrogen). Control siRNA (siCon) was purchased from Qiagen (All-Stars-372 
siRNA; siAll). The mouse Dyrk1b-specific siRNA was an equimolar pool of four target 373 
sequences: si1b_1: AUACAGAGAUGAAGUACUA; si1b_2: GCACAUCAAUGAGGUAUAC; si1b_3: 374 
GAGAUGAAGUACUACAUAG; si1b_4: GGACAAAGGAACUCAGGAA. The human DYRK1B-375 
specific siRNA target sequences were: si1B_3: GAGAUGAAGUACUAUAUAG; si1B_4: 376 
CGAAAGAACUCAGGAAGGA; si1B_5: GGUGAAAGCCUAUGAUCAU; si1B_6: 377 
GGACCUACCGCUACAGCAA.  378 
 379 
RNA preparation, cDNA synthesis, qPCR 380 
Total RNA was extracted using NucleoSpin RNA II kit (Macherey-Nagel) according to the 381 
manufacturer’s protocol. cDNA synthesis of 1 μg total RNA was performed using iScript cDNA 382 
Synthesis Kit (Biorad) following the manufacturer’s guidelines. Quantitative PCR reactions 383 
were performed using the Absolute QPCR SYBR Green Mix (ABGene). qPCR reactions were 384 
performed on 96 well qPCR plates (ABGene) using either the Mx3000P or Mx3005P qPCR 385 
systems (Agilent). Results were calculated as relative mRNA expression (2ΔΔCt). Data was 386 
obtained from at least three independent experiments and is shown as the mean ± StDev. 387 
Primer sequences (5’ to 3’) for the detection of mouse Dyrk1b were: For-388 
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TTGACACCTGCCCCTCCTCTAGCAC; Rev-GGCCCCCACAATATCGGTTGCTGTA. Human DYRK1B: 389 
For-TTGGCCAGGTGGTGAAAGCCTATGA; Rev-CAATCTGGGCCTGGTTCAGGAAAGC. Mouse 390 
Hdac6: For-TCCCTACAGCTTGGGGTTCTCAGCA; Rev-TCCCCAAATCCTTGTGTCAGCATCA. Mouse 391 
Mec17: For-TGACCGGGAGGCTCACAATGAGGTA; Rev-TGGGGCTCCACTCGCTCTTTCTGTA. All 392 
other primer sequences have been described elsewhere [16, 74-76]. 393 
 394 
Immunoblotting 395 
Separation of lysates by SDS-PAGE was followed by subsequent Western Blot analysis. SDS-396 
PAGE gels were blotted on Immobilon-PVDF membranes (Millipore) and incubated with the 397 
respective primary antibody, followed by an HRP-coupled secondary antibody. Detection of 398 
the HRP signal was performed using Pierce ECL Western Blotting Substrate (Thermo Fisher 399 
Scientific, Waltham, USA) according to the manufacturer’s protocol. The following primary 400 
antibodies were used: α-DYRK1A (#2771; Cell Signaling Technology (CST), Danvers, USA); α-401 
DYRK1B (#5672; CST); α-DYRK2 (#8143; CST); α-DYRK3 (sc-390532; Santa Cruz Biotechnology, 402 
Santa Cruz, USA); α-GLI1 (#2643; CST); α-phospho-GSK3βS9 (#5558, CST); α-total GSK3β 403 
(#12456, CST); α-acetylated α-tubulin (AcTub, T6793, Sigma-Aldrich, St. Louis, USA); α-404 
tyrosinated-α-tubulin; α-polyglutamylated-α/β-tubulin; α-α-tubulin (T6199, Sigma); α-Lamin 405 
B (sc-6217, Santa Cruz); α-GAPDH (#G9545; Sigma); α-β-Actin (#A5441; Sigma). 406 
 407 
Immunofluorescence on fixed samples 408 
Cells were seeded on cover slips and fixed with 4 % formaldehyde/PBS for 10 min at RT. 409 
After washing twice with PBS at RT for 5 min, cells were permeabilized with 0.5 % Triton-410 
X100/PBS at RT for 5 min. For immunostaining, cover slips were blocked with 10 % 411 
serum/PBS for 1 h at RT and washed with PBS at RT for 10 min. Primary antibodies were 412 
diluted in PBS containing 10 % serum and 0.1 % saponin and incubated overnight at 4°C. 413 
After washing twice with PBS at RT for 5 min, the cover slips were incubated with 414 
fluorophor-coupled secondary antibodies diluted in PBS containing 10 % serum and 0.1 % 415 
saponin at RT in the dark for 2 h. After washing twice with PBS for 5 min and rinsing with 416 
H2O, the cells were covered with mounting medium containing DAPI. Microscopy was 417 
performed on a Leica DMR epifluorescence and a Leica AF6000 widefield fluorescence 418 
microscope with 3D deconvolution software (Leica Microsystems, Wetzlar, Germany). 419 
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Microtubule-association assay (MTaa) 422 
Fully confluent NIH3T3 fibroblasts were incubated on 10 cm culture dishes in 0.5 % FBS-423 
containing DMEM with or without SAG (100 nM) for 48 h. Subsequently, cells were washed 424 
with warm PBS, scraped off and pelleted (300 g, 30 sec, RT), followed by resuspension in 425 
PBS/Taxol (20 µM) and incubation for 15 min at RT. After another centrifugation step (300 g, 426 
30 sec, RT), cells were resuspended in 1 ml of room-temperature MTaa lysis buffer (1 mM 427 
EGTA, 0.05 % NP-40, 3 mM MgCl2, 100 mM NaCl, 10 mM Tris pH 7.5 plus protease inhibitors) 428 
and an aliquot (400 µl) of the lysate was stored (whole cell lysate). The remaining cell lysate 429 
(600 µl) was layered on a cushion of cold MTaa lysis buffer containing 1M sucrose and 430 
centrifuged (400 g, 5 min, RT) to pellet the nuclear fraction. The supernatant was transferred 431 
to a new tube for ultracentrifugation (27.000 g, 45 min, RT) in order to pellet unwanted 432 
membrane debri. The supernatant was collected and another ultracentrifugation step was 433 
performed (100.000 g, 90 min, RT). The supernatant collected from this step was stored as 434 
cytoplasmic fraction and the pellet was taken as polymerized microtubule fraction. 435 
 436 
Cell polarization assay 437 
NIH3T3 cells were grown confluent on glass cover slips (24h) followed by another 24h in the 438 
presence of 100 nM SAG (0.5% FBS). Subsequently, DMSO, ACY1215 (10 µM) or AZ191 (0.5 439 
µM) was added for 30 min followed by wounding of the confluent monolayer with a yellow 440 
pipette tip. Cells were washed once with medium, followed by addition of 3% FBS-containing 441 
medium containing SAG/DMSO/ACY-1215/AZ191 for 6 h at 37° C. Cells were fixed with 3.7% 442 
formaldehyde, stained with antibodies against α-tubulin and pericentriolar material 1 443 
(PCM1) and mounted in Vectashield containing DAPI (Vectorlabs). Images shown in the 444 
manuscript are maximum intensity projections of 3D-deconvoluted Z-stacks taken on a Leica 445 
AF6000 widefield fluorescence microscope with 3D deconvolution software. 446 
 447 
Ground state depletion microscopy (GSD) 448 
GSD was performed on a Leica GSDIM Super Resolution SR microscope system according to 449 
the manufacturer’s protocols using AlexaFluor488- and AlexaFluor647-labelled secondary 450 
antibodies. In some cases, the soluble cytoplasm was washed out before fixation by gently 451 
shaking the cells for 2x 5min in 1M EGTA/2.5mM GTP/4% PEG-6000/0.1M PIPES/0.2% Triton-452 
X100 at room temperature.  453 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
 454 
Live cell measurement of mitochondrial transport 455 
Cells were grown in chamber slides (Ibidi) in 0.5% FBS for 48h with/without SAG (100 nM), 456 
followed by addition of DMSO, ACY-1215 (10 µM) or AZ191 (0.5 µM). Live cell imaging was 457 
started approx. 30 min later. Recordings were taken on a laser scanning confocal microscope 458 
(LSCM) (Leica TCS-SP8i) with an incubation chamber tempered to 37°C. Recordings were 459 
made in 10 min intervals from several slide areas for a duration of 3h (20x objective, NA 0.75, 460 
1024x1024 pixel, 2x average, zoom 3.0).  Analysis of mitochondria motility from three cells was 461 
done in Imaris software (Bitplane, v8.2.0) using the spot algorithm. The overall movement of 462 
the cells was set to zero by using the surface algorithm before mitochondria calculations. 463 
 464 
Statistical analysis 465 
Unless otherwise stated, data is presented as the mean of three independent experiments ± 466 
standard deviation (StDev). Statistical significance was calculated by applying a two-tailed 467 
student’s t-test. *p<0.05; **p<0.01; ***p<0.001.  468 
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Figure legends 678 
Figure 1: Hh signaling increases levels of DYRK1B and tubulin acetylation. 679 
(A) Immunofluorescent AcTub (green) staining of NIH3T3 cells treated with either DMSO, 680 
Smoothened agonist SAG (100 nM) or SANT1 (200 nM). Scale bars equals 10 µm. Blue 681 
= DAPI staining. 682 
(B) Quantification of AcTub intensities as shown in (A). Shown is the AcTub fluorescence 683 
intensity per cell measured in nine different viewing fields from 3 different 684 
experiments. The total cell number analyzed was 180-210. 685 
(C) Immunoblot of NIH3T3 cell lysates treated with SAG. Shown is a representative blot 686 
of three. 687 
(D) Quantification of (C) (mean of n=3 ±SD).  Values were normalized to GAPDH levels or 688 
total α-Tubulin (aTub). 689 
(E) Western blot of MEF lysates treated with SAG (100 nM, 48-72h). Shown is one blot of 690 
two. 691 
(F) Immunoblot of MEF cell lysates stably expressing SHH (MEF[SHH] cells). Cells were 692 
treated with the SMO antagonist SANT to block Hh signaling. Shown is a 693 
representative blot of three. 694 
(G) Western blot of MEF cell lysates transfected with control siRNA or with Dyrk1b-695 
specific siRNA. Cells were treated with SAG (100 nM, 48h). Shown is one blot of two. 696 
(H) Immunoblot depicting the changes in AcTub levels after RNAi-mediated knock-down 697 
of Dyrk1b in MEF[SHH] cells. Shown is one blot of two independent experiments. 698 
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 Figure 2: DYRK1B expression is sufficient to augment tubulin acetylation. 702 
(A) Bright field images of NIH3T3 cells stably expressing mock control (empty vector) or 703 
DYRK1B. Scale bar 50 µm. 704 
(B) Immunoblot of NIH3T3 cells stably expressing DYRK1B or empty vector control 705 
(mock) showing the expression levels of the indicated proteins. Shown is one 706 
representative blot of four.  707 
(C) AcTub immunofluorescence image (green) of control NIH3T3 (mock) or of cells with 708 
stable DYRK1B expression. 709 
(D) Quantification of the results obtained in panel (C). Shown is the mean of n=5 ±SD. 710 
AcTub= Acetylated α-tubulin. 711 
(E) Acetylated tubulin staining (green) in human Hela cells stably expressing DYRK1B or 712 
empty vector control (mock). Blue = Nuclei. Scale bar 100 µm. 713 
(F) Western blot verifying DYRK1B-V5 overexpression of cells depicted in (E). 714 
(G) Quantification of AcTub intensities of cells shown in (E). Shown is the mean of n=4 715 
±SD. 716 
(H) In vitro HDAC6 enzyme assay (mean of n=3 ±SD). Endogenous HDAC6 protein was 717 
immunoprecipitated from Hela cells stably expressing empty vector control (mock) or 718 
DYRK1B. HDAC6 activity was subsequently measured with a luminometric HDAC 719 
assay. Values were normalized against western blot band intensities of 720 
immunoprecipitated HDAC6 (see inset as example). The selective HDAC6 inhibitor 721 
Cay10603 (100 nM) was used as a positive control. 722 
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Figure 3: Hh and DYRK1B inactivate GSK3β by Ser9 phosphorylation. 728 
(A) Western blot example of n=2 independent experiments showing phospho-GSK3βS9 729 
levels after SAG induction. 730 
(B) Western blot data and the corresponding quantification (mean of n=3 ±SD) of 731 
MEF[SHH] cells treated with the SMO inhibitor SANT (200 nM, 48-72h). 732 
 733 
(C) MEF[SHH] cell lysates transfected with control siRNA (siCon) or with Dyrk1b-directed 734 
siRNA (si1B). Shown is one representative blot of three. 735 
(D) Western blot of NIH3T3 lysates. Cells were pre-treated with SAG (100 nM) for 48h 736 
prior to addition of the DYRK1B inhibitor AZ191 (AZ, 0.1 or 0.5 µM) for 3h. 737 
(E) Quantification of Phospho-GSK3βS9 levels in NIH3T3 stably expressing empty vector 738 
(mock) or V5-tagged DYRK1B in two different serum concentrations (mean of n=3 739 
±SD). Inset: One representative blot. 740 
(F) Quantification of in vitro kinase assays with recombinant DYRK1B enzyme and 741 
immunoprecipitated GSK3β. Shown is the mean of n=3 ±SD. Rec.1B = Recombinant 742 
DYRK1B. The inset depicts a representative blot. 743 
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Figure 4: DYRK1B is associated with microtubules. 747 
(A) Microtubule-association assay (MTaa) of lysates derived from control NIH3T3 cells or 748 
of cells treated with SAG (100 nM, 48h). WCE = Whole cell extract; Nuc = Nuclear 749 
fraction; Cyt = Cytoplasmic fraction; MT = Polymerized MT-containing pellet. The 750 
levels of endogenous HDAC6 in control NIH3T3 cells were too low to be detected by 751 
Western blotting. Lamin B (mainly WCE + Cyt fractions) was included to demonstrate 752 
purity of fractions. Shown is one representative experiment of n=3. 753 
(B) Super resolution images by means of Ground State Depletion (GSD) microscopy 754 
showing transiently transfected human PSC cells. Left panel: Mock-transfected; right 755 
panel: DYRK1B-V5 transfected. Red = endogenous β-tubulin. Green = V5-antibody. 756 
The orientation of microtubules is indicated as faint white dotted lines in the insets. 757 
A scale bar of 2.5 µm is given. 758 
(C) GSD-image of non-transfected Hela cells. Red = endogenous α-tubulin. Green = 759 
endogenous DYRK1B. 760 
(D) GSD-image of non-transfected PSC cells. Red = endogenous α-tubulin. Green = 761 
endogenous HDAC6. The soluble cytoplasm has been washed out before in this 762 
experiment. 763 
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Figure 5: Hh signaling facilitates organelle transport. 765 
(A) Confocal image of NIH3T3 cells stably expressing a Cox8a-Dendra2 fusion 766 
construct (NIH[Cox8a-Dendra]; green). In addition, cells were co-stained with 767 
MitoTracker (Red). Nuclei appear in blue. Scale bar represents 10 µm. 768 
(B) Levels of DYRK1B and acetylated tubulin in SAG (100 nM, 48h)- and AZ191 769 
(DYRK1B inhibitor, 0.5 µM for last 2h)-treated NIH[Cox8a-Dendra] cells. 770 
(C) Track length of mitochondria movement over a 3h time window in NIH[Cox8a-Dendra] 771 
cells. Shown is one representative experiment (20x objective) measuring three 772 
different cells of n=4 independent experiments. At least 500 events were 773 
recorded for each condition. Drug concentrations were: ACY-1215 (ACY, HDAC6 774 
inhibitor) 10 µM; SAG 100 nM; AZ191 0.5 µM (all in 0.5%FBS). 775 
(D) Speed of mitochondria movement over a 3h time window in NIH[Cox8a-Dendra] cells. 776 
Shown is one representative experiment (20x objective) measuring three 777 
different cells of n=4 independent experiments. At least 500 events were 778 
recorded for each condition. Drug concentrations were: ACY-1215 (ACY) 10 µM; 779 
SAG 100 nM; AZ191 0.5 µM (all in 0.5%FBS). 780 
(E) Mean square displacement (MSD) over time. Shown is the MSD calculation 781 
(exponential curve fitting) of the experiment depicted in panels (C) and (D). An 782 
increase in directed transport is reflected as an increased slope. 783 
 784 
 785 
786 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
28 
 
Figure 6: Hedgehog promotes mesenchymal cell polarization and cell migration. 787 
(A) Microscopic determination of NIH3T3 fibroblast polarization by means of MTOC 788 
(PCM1, red) and α-tubulin (green) staining. Nuclei appear in blue. The orientation of 789 
the scratch is indicated by a white dashed line. Positive polarization towards the 790 
wound is indicated by a white asterisk. For experimental details see materials and 791 
methods section. 792 
 793 
(B) Quantification of the polarization experiment depicted in (E) (mean of n=3 ±SD). SAG 794 
(SMO agonist, 100 nM); ACY-1215 (HDAC6 inhibitor, 10 µM). 795 
 796 
(C) Fraction of polarized NIH3T3 fibroblasts, pre-treated with SAG (100 nM) for 2d, 797 
followed by scratch wounding. DMSO or AZ191 (DYRK1B inhibitor, 0.5 µM) was 798 
added 30 min before the scratch. Shown is the mean of n=3 ±SD. 799 
 800 
(D) Example of scratch wounds in confluent NIH3T3 cultures directly after scratching 801 
(Start, left), after approx. 9.5h (Mid, middle) or at the end (approx. 20h, right panel). 802 
The border is outlined by a dashed line. AZ = AZ191 (1µM). 803 
 804 
(E) Relative wound closure over time as assessed by live cell recording. One 805 
representative example of three is shown. AZ = AZ191 (1µM). 806 
 807 
(F) Schematic depiction of the findings described in this manuscript. Left panel: Without 808 
Hh stimulation. Right panel: With Hh stimulation. Not shown is the possibility that 809 
Hh/SMO might also activate AKT, leading to an additional route of GSK3β regulation. 810 
DYRK1B can also functionally interact with AKT. 811 
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Abstract: Hedgehog (Hh)/GLI signaling is an important instructive cue in various processes
during embryonic development, such as tissue patterning, stem cell maintenance, and cell
differentiation. It also plays crucial roles in the development of many pediatric and adult malignancies.
Understanding the molecular mechanisms of pathway regulation is therefore of high interest.
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) comprise a group of protein
kinases which are emerging modulators of signal transduction, cell proliferation, survival, and cell
differentiation. Work from the last years has identified a close regulatory connection between DYRKs
and the Hh signaling system. In this manuscript, we outline the mechanistic influence of DYRK
kinases on Hh signaling with a focus on the mammalian situation. We furthermore aim to bring
together what is known about the functional consequences of a DYRK-Hh cross-talk and how this
might affect cellular processes in development, physiology, and pathology.
Keywords: hedgehog; GLI1; dual-specificity tyrosine-regulated kinase; DYRK; MIRK; Down syndrome
1. Introduction
1.1. The Hedgehog Signaling Pathway
The Hedgehog (Hh) gene was first identified in genetic screens for mutations that disrupt the
larval body plan in Drosophila melanogaster [1]. The name Hedgehog originates from the short and
‘spiked’ phenotype of the cuticle of the Hh mutant Drosophila larvae, which resembles the spikes
of a hedgehog [1,2]. The members of the Hh family of proteins have since been recognized as key
mediators of many fundamental processes in embryonic development, playing a crucial role in
controlling cell fate, patterning, proliferation, survival, and differentiation. Furthermore, Hh signaling
also regulates the maintenance of tissue stem cells and affects oncogenic transformation and the
development of tumors [3–5]. Vertebrates possess three Hedgehog homologues: Desert (DHH),
Indian (IHH), and Sonic (SHH). All three genes have evolutionary conserved roles in body plan
organization and development [2,6–8]. The polarizing activity of the organizing centers located
in the limb bud, the notochord, or the floor plate of the neural tube is regulated by SHH [9,10].
IHH regulates the coordination of multiple cellular events during endochondral bone development
including osteoblast differentiation [11,12], while DHH is required for the development of germ cells
in testes and peripheral nerve sheath formation [13].
The Hh signaling cascade has been discussed in depth by other excellent reviews of this special
issue on embryogenesis (e.g., [14–17]). Briefly, the canonical Hh signaling cascade is initiated in the
target cell by the Hh ligand binding to the Patched1 receptor (PTCH1) [18,19], a 12-span transmembrane
protein located in the ciliary membrane relieving the repression of Smoothened (SMO) [20,21], a 7-span
transmembrane protein, which is a member of the G protein-coupled receptor (GPCR) superfamily.
J. Dev. Biol. 2017, 5, 13; doi:10.3390/jdb5040013 www.mdpi.com/journal/jdb
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This de-repression results in the activation of the Hh transcriptional effectors, the zinc finger proteins
of the GLI (Cubitus interruptus (Ci) in Drosophila melanogaster) family [22].
Several studies have reported the modulation of Hh signaling through protein kinases,
amongst others PKA, PKC, GRK2, MEK, ERK, AKT, S6K, and GSK3β all of which have been
documented to play a role in Hh signal transduction [23–28]. Moreover, recent studies have outlined
the importance of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) in the positive
and negative regulation of Hh pathway activity [29–36]. This review centers on the DYRK family of
kinases and their role in regulating the developmentally important Hh signaling pathway.
1.2. Protein Kinases: An Introduction
Protein kinases are central for the regulation of major cellular processes. Kinases play particularly
prominent roles in signal transduction as they direct the cellular activities by the addition or removal of
a phosphate group. As abnormal levels of protein phosphorylation are associated with the development
of several diseases [37], it is crucial to delve deeper into the understanding of the varying mechanisms
that control these phosphorylation events [38]. Eukaryotic protein kinases (ePKs) are divided into
nine large groups (plus one atypical group which does not show similarity to ePKs), which are further
divided into families and subfamilies [39,40]. These groups are: (1) Tyrosine kinases (TK); (2) Tyrosine
kinase-like (TKL); (3) cAMP-dependent protein kinase, cGMP-dependent protein kinase and protein
kinase C (AGC); (4) Calcium/calmodulin-dependent kinases (CAMK); (5) Casein kinase 1 (CK1);
(6) Cyclin-dependent kinases (CDK), Mitogen-activated protein kinases (MAPK), Glycogen synthase
kinase (GSK3) and CDC-like kinase (CLK) group of protein kinases (CMGC); (7) Homologs of the
yeast STE7, STE11 and STE20 genes (STE); (8) Receptor Guanylate Cyclases (RGC); and (9) Others
(kinases that do not fit within any of the other main kinase groups) [40–42].
2. The CMGC Group of Kinases
Due to sequence homologies in their kinase domains, CDKs, MAPKs, GSK3s, CLKs, and related
kinases (CMGCs) form one big group of eukaryotic protein kinases [40]. The CMGC group consists
of 62 members in total, which are subdivided further into nine families (CDK-, CDKL-, GSK-, CLK-,
MAPK-, HIPK-, DYRK-, RCK-, and SRPK-families) [43]. This group is highly conserved during
evolution, arguing that its members fulfill important functions from nematodes to humans. Given their
involvement in cell proliferation, MAPKs and CDKs are the most studied kinases within the CMGC
group and are the subject of intense research efforts in oncological research. Less studied candidates
include the dual-specificity tyrosine regulated kinases (DYRKs) and the serine-arginine protein kinases
(SRPK). In general, the kinases in the CMGC group have a broad spectrum of functional roles
ranging from signal transduction to cell cycle regulation, RNA related processing, and intracellular
communication [43].
3. The DYRK Family of Kinases
Dual-specificity tyrosine phosphorylation-regulated kinases belong to the CMGC group of kinases
and contain a characteristic sequence motif called the DYRK-homology box (DH box) (Figure 1).
YAK1 from budding yeast was the first member of the DYRK family to be discovered [44,45]. There are
five members within the mammalian DYRK subfamily and they are categorized into two classes.
Class I consists of DYRK1A and DYRK1B (the latter is also known as Minibrain-related kinase (Mirk)),
while class II is made up of DYRK2, DYRK3, and DYRK4 [45,46]. The assortment of mammalian
DYRKs in the corresponding classes is based on sequence homologies within the conserved kinase
domain [46,47]. Certain sequence motifs can only be found in class I DYRKs, such as a C-terminal PEST
domain (a region rich in proline (P), glutamic acid (E), serine (S), and threonine (T)) (Figure 1). The PEST
sequence is known to act as a signal for rapid protein degradation [48]. However, to our knowledge,
this function has not been formally proven in DYRKs. DYRK1A protein stability is regulated through
the ubiquitin/proteasome system, but involves an N-terminal region [49]. DYRK1A is the only
J. Dev. Biol. 2017, 5, 13 3 of 16
family member containing a poly-histidine stretch (13 consecutive histidine residues) and a region
enriched in serine/threonine residues (S/T-rich region) [50,51]. The poly-histidine stretch promotes
the targeting of DYRK1A to nuclear speckles which are enriched with pre-mRNA splicing factors
regulating the splicing machinery [51,52]. Other elements, such as nuclear localization signals (NLS),
can be found in many DYRKs. On the other hand, only class II DYRK kinases contain a N-terminal
auto-phosphorylation accessory region (NAPA) domain, which is thought to be required for tyrosine
auto-phosphorylation specifically in class II DYRKs, although DYRK2 lacking the NAPA domain
has been shown to auto-phosphorylate itself under in vitro conditions [47,53–55]. Further differences
include the extent of the respective N- and C-termini (Figure 1). In general, DYRK family members are
known to regulate protein stability, cell proliferation, and differentiation. These events are mediated
by the phosphorylation of DYRK recognition sites in target proteins. The consensus sequence motif
consists of Ser or Thr followed by Pro in position +1. Furthermore, an arginine residue at position
−2 or −3 relative to Ser/Thr seems to be preferred (RxxS/TP or RPxS/TP), although a considerable
degree of divergence to this consensus has also been noted [47,56].
The activation loop of DYRK kinases contains a conserved YXY sequence, the phosphorylation
of which leads to the activation of full enzymatic activity. Members of the DYRK family
auto-phosphorylate the second tyrosine residue in order to be fully activated and then phosphorylate
substrates in trans on Ser/Thr residues, hence they are known as Dual-specificity tyrosine-regulated
kinases [45,47,56]. The auto-activation mode of DYRKs is in contrast to MAP kinases, where an
upstream kinase is needed for the phosphorylation of the activation loop [47]. The tyrosine specificity
of DYRK kinases is thought to be lost once the protein is fully translated and only the Ser/Thr specificity
on target proteins remains [53,57].
− −
 
Figure 1. Schematic representation of the DYRK family of proteins: Distinct sequence motifs such as
the nuclear localization signal (NLS); DYRK-homology box (DH); a motif rich in proline, glutamic acid,
serine, and threonine residues (PEST); a poly-histidine stretch (HIS); a serine/threonine rich region
(S/T); a N-terminal auto-phosphorylation accessory region (NAPA); and a conserved kinase domain
comprising the structural and functional features of DYRKs.
4. Class I DYRKs: DYRK1A and DYRK1B
4.1. The DYRK1A Kinase
DYRK1A is a nuclear kinase, but can also be found in the cytosol. It represents the most studied
member of the DYRK family, which is due to its presumed involvement in the Down syndrome
(DS, OMIM #190685). DS is one of the most common genetic defects in humans with an estimated
incidence of about 1 in 1000 live births worldwide and is caused by the complete or partial duplication
of human chromosome 21 (trisomy 21) [58,59]. In humans, the DYRK1A gene is located on chromosome
21 (21q22.13), which is part of the so-called Down-Syndrome Critical Region (DSCR) [60]. Genes present
within the DSCR (21q22.1–22.3 encompassing 33 genes) are thought to account for the development of
DS, characterized by a general intellectual impairment, characteristic craniofacial dysmorphologies,
and congenital heart disease [60–62].
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Despite the fact that upstream modulators of DYRK1A kinase activity exist [63,64], the prime
determinant of DYRK1A protein function is considered to be its overall protein amount making it
very sensitive to gene dosage. An altered copy number of the DYRK1A gene in mammals or of its
orthologous gene, minibrain (mnb) in Drosophila, impedes with the proper development of the central
nervous system [65]. Different studies with the trisomic DS mouse model Ts65Dn or cells derived from
Down syndrome patients [66] have shown that an increased kinase expression affects neurogenesis
and neuroblast proliferation, and results in impaired behavioral phenotypes. Genetic overexpression
of Dyrk1A in mice leads to behavioral and cognitive impairment and neuronal alterations [67–69].
In contrast, loss of function of Dyrk1A or mnb results in significant brain size reduction in mice [70],
flies [65,71], and men [72].
Intriguingly, a recent study identified DYRK1A loss-of-function mutations which are associated
with impaired dendritic and spine growth, cortical development, and the pathophysiology of
autism [73]. The exact mechanisms underlying DYRK1A’s effects on dendritogenesis and neurogenesis
remain open, but might involve its role in actin regulation [36,74–77]. Furthermore, DYRK1A
has functions in synaptogenesis and synaptic vesicle endocytosis [74,78]. Haplo-insufficiency
of DYRK1A is associated with the development of autosomal dominant mental retardation-7
(MRD7) (OMIM #614104), a syndrome characterized by primary microcephaly, facial dysmorphism,
and behavioral problems [79]. Also, DYRK1A expression might be epigenetically misregulated in the
William-Beuren region duplication syndrome (WBS) (OMIM #609757). WBS phenotypes commonly
include craniofacial anomalies and cognitive deficits ranging from mental retardation to autism [80,81].
The documented evidence of DYRK1A functioning in brain development suggests that it interacts
with embryonic signaling pathways such as Hedgehog, which is known to be crucial for neuronal
specification in the neural tube, hippocampal neural stem cell maintenance, and the development of the
cerebellar cortex [82,83]. Mice with a genetic Shh knockout present with Cyclopia [84], and inactivating
mutations in the human SHH gene cause holoprosencephaly (OMIM #236100), a common form of
structural malformation of the developing brain hemispheres [85–87]. In contrast, human patients
suffering from the Hh-activating Gorlin syndrome (Basal Cell Nevus Syndrome, OMIM #109400) have
an increased brain size [88].
4.2. DYRK1A as a Regulator of (Neuronal) Hedgehog Signaling
The fact that both Hh signaling and the DYRK1A kinase have such important roles in embryonic
brain development suggests that they might be functionally linked. The exact interplay between
DYRK1A and Hh signaling seems to be complex and stimulatory, and inhibitory functions have
also been described (Figure 2). Indeed, suppression of Hh pathway activity was seen in cerebellar
cells derived from a Down syndrome mouse model [89]. Furthermore, some morphological as well
as functional deficits could be ameliorated by the application of a synthetic SMO agonist or by
genetic Hh pathway activation [90,91], suggesting a too low level of Hh signaling in DS. Subsequent
mechanistic studies revealed that increased levels of the DSCR-localized DYRK1A kinase can dampen
Hh signaling [92], most likely through its effect on the actin cytoskeleton and on actin-regulated
transcriptional regulators [36]. For instance, DYRK1A can phosphorylate the F-actin stabilizing
ABLIM proteins and thereby functionally exert a negative impact on the actin cytoskeleton and on
actin-modulated transcriptional co-factors such as MAL (MKL1, MRTF), which also modulate the Hh
pathway [36]. This mechanism might explain why DS cerebellar cells display a limited response to
Purkinje cell-derived SHH (Figure 2). However, this finding was unexpected as previous reports had
proposed a direct activating function of DYRK1A on GLI1. Specifically, DYRK1A can phosphorylate
amino acid residues in the N-terminus critical for the nuclear import of GLI1 [31,32,36,92] (Figure 2).
As a result, the impact of DYRK1A on Hh signaling might be context-dependent and might also
be dictated by the exact mode of pathway activation (ligand/receptor-triggered versus direct GLI1
activation). Further investigations are certainly needed to clarify this point.
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Hypothetically, a physiological connection between Hh signaling and DYRK1A might also exist in
the case of neural stem cell (NSC) division. In general, stem or progenitor cells can undergo symmetric
or asymmetric types of cell division in order to generate progeny [93]. Hh signaling preferentially
supports symmetric cell divisions [94,95]. DYRK1A has also been implicated in signaling aspects
during asymmetric versus symmetric neural stem cell division, although the details await further
investigation [96,97]. In general, Hh pathway activity has been associated with brain size (see above),
which might be caused by its positive effects on neural stem cell pools. Intriguingly, truncation of
DYRK1A results in the stimulation of kinase activity [98] and DYRK1A gene truncations have been
found in human microcephaly [72]. Finally, it is interesting to note that Down syndrome patients have
a reduced risk of developing solid cancer. The fact that DYRK1A is capable of suppressing canonical
Hh signaling might contribute to its described potential as a tumor suppressor [99–103], in addition to
other Hh-independent proposed mechanisms [104,105].
In addition to the neuronal effects of DYRK1A, one report exists describing the Hh-related impact
of DYRK1A and its physical interactors HAN11 and mDia1 in cultured sebocytes [106]. Overexpression
of either HAN11 or mDia1 suppressed GLI1 nuclear localization and activity in reporter assays and
slowed the growth of these cells. In the murine embryo, Han11 is expressed in the developing limb
bud (E10.5), together with Gli1 and Ptch1. It is possible that the actin-regulating formin mDia1 is
functionally linked to the aforementioned DYRK1A-ABLIM-Actin-MAL-GLI axis, but experimental
proof is lacking at this point.
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Figure 2. Schematic depiction of the cross-talk between Hh signaling and DYRK kinases.
Three DYRK kinases (DYRK1A, DYRK1B, DYRK2) have been described as regulators of
upstream (above GLI transcription factors) and downstream (at the level of GLI transcription
factors) Hh signaling. As Hh pathway modulators, they might control important embryogenic
and developmental processes, such as myogenesis, neurogenesis, or the pathophysiology of Down
syndrome. Literature references are given in square brackets.
4.3. The DYRK1B Kinase
The closest relative of mammalian DYRK1A is the DYRK1B kinase, also referred to as MIRK
(Minibrain-related kinase). The human DYRK1B gene is located on chromosome 19q13.2, a region often
amplified in ovarian and pancreatic cancer [107,108]. This kinase has three splice variants (629aa (p69),
601aa (p66), and 589aa (p65)) and is expressed in abundance in human skeletal muscle and testes [109].
Human DYRK1A and DYRK1B proteins are 84% identical in the N-terminal and catalytic domains but
show no extended similarity in the C-terminal domain. Human and mouse DYRK1B proteins share
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97% sequence similarity [46,110–113]. In many different cell types, DYRK1B can be found both in the
nucleus and in the cytoplasm [114].
4.4. DYRK1B in Developmental and Physiological Processes
The observation that DYRK1B is strongly expressed in skeletal muscle argues for a physiological
role in muscle function and/or development. Indeed, DYRK1B levels have been shown to be
comparatively low in myoblasts, but to increase significantly upon the induction of differentiation [115].
DYRK1B favors myoblast fusion and the subsequent expression of differentiation markers [116].
Furthermore, DYRK1B supports the survival of muscle progenitor (C2C12) cells in culture and of cells
from muscle-related tumors such as rhabdomyosarcoma [117,118]. The pro-differentiating effects of
DYRK1B on myoblasts are opposite to the effects which Hh signaling exerts on muscle stem cells
(satellite cells) and on C2C12 progenitor cells [119]. Here, Hh promotes cell division and blocks
differentiation along the myogenic lineage, thereby maintaining the progenitor cell pool. Although
it is not clear whether the influence of Hh or DYRK1B occurs exactly at the same developmental
stage, currently available data would suggest a primarily antagonistic relationship between these two
pathways. Recent work has identified a complex regulatory relationship between DYRK1B and Hh.
While DYRK1B dampens Hh signaling initiated by SMO, it also promotes the stability of the GLI1
transcription factor on the other side [29,30,34]. The latter might be mediated by DYRK1B-induced
stimulation of the pro-survival PI3K-AKT signaling pathway, a known positive regulator of GLI
stability [23,120] (Figure 2). In addition, at least in cultured fibroblasts, Hh pathway stimulation
increases DYRK1B protein levels by currently unknown post-transcriptional mechanisms [29],
suggesting a feedback loop.
Another example of physiological cross-talk between DYRK1B and Hh might be the differentiation
of mesenchymal progenitor cells into adipocytes. Hh signaling has a generally inhibiting
impact on adipocytic differentiation, usually redirecting cellular fate towards the osteogenic
lineage [121–123]. In contrast, DYRK1B favors the in vitro differentiation into adipocytes [35].
This holds particularly true for DYRK1B carrying mutations which were identified in families suffering
from an autosomal-dominant form of metabolic syndrome [35], a disease with prominent adipocyte
involvement. The mutations found result in misfolding of the DYRK1B protein and in intracellular
aggregation [124]. It remains to be clarified how these mutations affect the functional integration of
DYRK1B into other signaling pathways, but it is intriguing to note that mutant DYRK1B expression
reduced GLI2 levels in cultured adipocytes [35]. It is therefore reasonable to speculate that the
suppression of Hh pathway activity contributes to these effects.
5. The Class II DYRKs
5.1. The DYRK2, DYRK3, and DYRK4 Kinases
Compared to the DYRK class I members, the class II DYRKs (DYRK2, DYRK3, DYRK4)
contain a larger N-terminal region and a shorter C-terminal domain. DYRK2 and DYRK4, but not
DYRK3, possess an NLS sequence and all three contain an NAPA (N-terminal autophosphorylation
accessory region) domain which is absent in class I DYRKs [47]. The NAPA domain provides
a chaperone-like function and transiently converts class II DYRKs into intramolecular tyrosine
kinases [54]. Despite lacking an apparent NLS, DYRK3 (also named REDK) is localized in the nucleus
in hematopoetic cells [125], whereas DYRK2 is mostly cytosolic, but under conditions of genotoxic
stress, it accumulates in the nucleus regulating p53 [126]. DYRK4, which is currently the least studied
DYRK family member, displays splice variant-dependent subcellular localization [47].
In contrast to DYRK1B, which has been described as an oncogenic kinase in numerous cancer types,
DYRK2 can also exert opposite functions and can display tumor suppressive traits. This is brought
about by DYRK2’s ability to activate p53-dependent apoptosis following DNA damage [126,127]
and by negatively controlling the protein stability of well-established oncogenes such as c-MYC
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or c-JUN [128]. Phosphorylation-dependent regulation of proteasomal degradation seems to be a
recurrent mechanism employed by many if not all DYRK kinases [129–134].
5.2. Class II DYRKs in Development
In zebrafish, DYRK2 has been shown to be expressed in lateral somites (mesodermal blocks around
the anterior-posterior axis of the developing embryo) and adaxial cells (muscle precursor cells that are
adjacent to the notochord and part of the presomitic mesoderm) at an early stage of embryogenesis [135].
Co-localization of Dyrk2 mRNA and myogenic differentiation factor D (MyoD) mRNA was seen in muscle
progenitor cells in the posterior compartment of somites. Here, DYRK2 might positively regulate fast
twitch muscle differentiation in the early stages of embryonic development [135]. Although the link
has not yet been experimentally verified, it is intriguing to note that in contrast to DYRK2, Hh signaling
promotes the formation of slow-twitch fibers in zebrafish [136]. Furthermore, mammalian DYRK2 has
been shown to negatively regulate Hh pathway activity by phosphorylating and degrading GLI2 [33]
(Figure 2). It is therefore reasonable to speculate that DYRK2, through its negative influence on Hh
signaling, might impact on the slow/fast-twitch fiber differentiation during muscle development.
A similarly antagonistic relationship between DYRK2 and Hh signaling might also play a role in
Drosophila, which encodes three DYRKs: Minibrain/Dyrk1A, DmDyrk2, and DmDyrk3. Recent reports
have shown that DmDyrk2 is expressed in the developing third antennal segment, an anatomical
structure responsible for smell, and in the morphogenetic furrow of the developing eye, where
it contributes to the development of the visual system [137]. In addition, Hedgehog is a known
regulator of morphogenetic furrow progression and ommatidial cell differentiation in the Drosophila
eye disc [138,139]. If, in analogy to mammals, DmDYRK2 also regulates Hh signaling, it is intriguing to
hypothesize that functional DYRK2-Hh cross-talk is involved in the specification of the Drosophila eye.
In comparison to class I DYRKs and DYRK2, the class II family members DYRK3 and DYRK4
show a very restricted expression profile with the strongest expression in erythroid progenitors and
testes, respectively [140,141]. As can be assumed from this expression pattern, DYRK3 is involved in
erythropoiesis. While Dyrk3−/− mice surprisingly present without a hematological phenotype, they
develop increased numbers of red blood cells under conditions of anemia, suggesting that DYRK3
functions as a negative regulator of erythropoiesis [140]. Therefore, small-molecule DYRK3 inhibitors
might be of interest to ameliorate anemic conditions. Although Hh ligands (mostly DHH and IHH)
have also been shown to regulate erythropoiesis [142–144], it currently remains unclear whether
cross-talk between DYRK3 and Hh signaling contributes to this process.
Significantly more work has been done on the function of DYRK3 on the cellular and molecular
level, albeit a clear link to Hh signaling has so far not been established. Specifically, DYRK3 impinges on
stress-associated mTOR signaling [145], as well as on endocytosis dynamics [146]. Endocytic sorting of
SHH and PTCH1 in clathrin-coated vesicles is also critical for proper Hh signaling in signal producing
and receiving cells [147–149]. However, whether DYRK3 is indeed involved in these steps awaits
further experimentation.
Of all the DYRK kinases discussed so far, the least is known about DYRK4. The expression
of this family member is strongly restricted to testicular tissue, with a strikingly selective peak of
expression in step VIII spermatids [46,141], suggesting a role in male fertility. Surprisingly, however,
analysis of Dyrk4 null animals revealed no aberrant sperm phenotype or defects in male fertility [141].
DYRK4 was shown to be present in the duck ovary, and was more active or upregulated in the high
egg production ovaries, which would suggest a hitherto unrecognized role in the female reproductive
system, at least in some species [150]. Desert Hh (DHH) signaling also occurs in testes and, at least in
certain species, also in ovaries, but the involvement of DYRK4 in DHH-mediated processes is unclear
at the moment [151–153].
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6. Conclusions
DYRK kinases are highly conserved during evolution from yeast to humans. Due to the
evolutionary diversification, DYRKs might represent the requirement of more critical and specialized
functions in vertebrates or might have contributed to this diversification. Multifaceted roles of DYRK
kinases have been discussed in this review and their importance in various developmental processes
has been stated. As of now, three of five mammalian DYRK kinases have been functionally linked
to Hh signaling (DYRK1A, DYRK1B, DYRK2), arguing for a close regulatory connectivity to the
developmentally important Hh system. Hence, although DYRK kinases are not absolutely required
for Hh signaling, they function as modulators and it is therefore reasonable to hypothesize that
they contribute to many Hh-driven steps during embryonic development. Unfortunately, however,
more work is needed to provide a clear picture of the exact and tissue-specific cross-talk between
DYRKs and Hh, particularly in in vivo settings. As certain DYRKs have a preferred expression
in specific tissues (e.g., DYRK1A in neuronal and DYRK1B in muscle tissue), it is reasonable to
speculate that the impact on the tissue-selective Hh pathway activity is specified by the respective
DYRK enzyme. In other tissues or cell types, where several DYRK kinases are expressed together
at comparable levels, a certain degree of functional redundancy might exist, particularly for the
class I DYRKs. These questions are important to address in the future in light of the development
of small-molecule inhibitors which might lack the necessary specificity and target several DYRKs
simultaneously. Complicating the developmental interpretation is the fact that DYRK kinases also
modulate other, non-Hh signaling systems, such as, e.g., the NFAT (nuclear factor of activated
T-cells) [154] pathway or HIF (hypoxia-inducible factor) signaling [155]. Future work will reveal
whether Hedgehog or any of the other signaling systems is particularly important for the physiological
impact of DYRK kinases.
Most evidence for developmental cross-talk between DYRKs and Hh stems from studies on
DYRK1A, neuronal development, and the Down syndrome. In addition, available data encourage
speculations on DYRK1B and DYRK2 modulating Hh signaling in muscle development and on the
involvement of DYRK1B in adipocyte differentiation. In light of recent reports strengthening the
concept of Hh-pathway modulation by DYRKs in pathological conditions such as metabolic syndrome
or cancer, it will be interesting to see whether future research unveils more cross-talk between this
group of kinases and the Hh system in physiological processes. In this review, we have tried to outline
the currently available knowledge on the DYRK family of kinases engaging in developmental biology,
physiology, and pathology, focusing on its impact on Hh signaling.
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